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ABSTRACT
A panel of eleven monoclonal antibodies of the IgG and IgM class were 
developed against the HM 175 strain of the Hepatitis A virus. Immunoglobulin 
specificity for the Hepatitis A virus was determined and the antibodies were applied 
toward the development of an antigen capture assay linked to a nucleic acid 
amplification step, (RT-PCR), for detection of the Hepatitis A virus. The 
neutralizing mouse monoclonal antibody and a rabbit polyvalent serum were assessed 
as capture antibodies for the immunoaffinity stage of the assay. Fifty microliter 
microfuge tubes were coated with the capture antibody. Formalin inactivated HAV 
was diluted to concentrations ranging from 108 to 102 virions per aliquot. After 
incubation the virion capsids were disrupted by heating and the viral genome was 
reverse transcribed. A conserved diagnostic sequence of 191 base pairs was selected 
for amplification and detection of the HA virus. After the RT step, the reaction was 
supplemented for the PCR step. After amplification, the amplified products were 
resolved by agarose gel electrophoresis.
The genome regions of capsid proteins VP1 and VP3 of the Hepatitis A virus 
(HAV) were individually amplified by PCR. Oligonucleotide primers containing 
flanking restriction endonuclease sequences were designed for amplification of the 
capsid genes. The expression vectors pTTQ18 and pAX4b+ were selected for 
generation of /3-galactosidase HAV fusion peptides. The fusion products contained 
either the alpha (a) fragment (pTTQ18) or the entire j8-galactosidase peptide
(pAX4b+). The recombinant peptides were expressed in Escherichia coli. Rabbit 
anti-HAV sera raised against the intact HA virion reacted with the recombinant 
peptides by immunoblot and enzyme immunoassay. A neutralizing mouse 
monoclonal antibody generated against the intact HAV reacted only against the VP1 
recombinant peptide by immunoblot and enzyme immunoassay. Affinity purification 
of the recombinant HAV peptides resulted in higher recovery of the fusion peptide 
containing the entire /3-galactosidase molecule. Cleavage of the VP1 recombinant 
peptide generated in the pAX expression vector system was assessed. The cleaved 
peptides reacted with both the rabbit polyvalent and the monoclonal antibody. A 
peptide corresponding to the expected size of VP1 (33 kDa) was demonstrated by 
immunoblot.
BACKGROUND
Hepatitis is a general term referring to inflammation of the liver that may 
result from exposure to a variety of chemical, physical, parasitic, bacterial, and viral 
agents. When induced by noninfectious causes, hepatitis may occur as a 
complication from drug hypersensitivity reactions, drug toxicity, biliary obstruction, 
or primary biliary cirrhosis. The extent of liver damage can range from mild cell 
damage detectable by biochemical tests for liver function, to fulminant disease with 
massive necrosis resulting in coma and death.
Viral infections that may produce hepatitis include infectious mononucleosis 
(Epstein Barr virus), Cytomegalovirus infection, Serum Hepatitis (Hepatitis B virus), 
non-A non-B Hepatitis, Enterovirus infection (mostly observed as a mild infection in 
children whereas in adults it manifests as a more severe infection).
Other uncommon viral infections that may present or cause inflammation of 
the liver include Herpes simplex virus (as a result of disseminated and systemic 
infection), Rubella virus (observed in congenital rubella), Yellow fever virus (liver 
is the target of this acute febrile disease), and Varicella-zoster virus.
Viral hepatitis when caused by an enterovirus infection is commonly referred 
as acute hepatitis. The causative agent has been classified as a member of the genus 
Enterovirus in the Picornaviridae family, and is referred to as the human Hepatitis A 
virus or human Enterovirus 72.
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The Hepatitis A virus, like all members of this genus, is a small, 
nonenveloped virus with an icosahedral capsid composed of 60 copies of four 
structural polypeptides; VP1 (33,000 D), VP2 (27,000 D), VP3 (23,000 D), and 
VP4 (2,500 D). This nonenveloped virus exhibits a diameter of 28 nanometers and 
possesses remarkable stability in ether, acidic conditions, such as pH 3.0, and 
heating for prolonged periods of time (76). The nonenveloped capsid encloses a 
linear, positive sense, single stranded infectious RNA molecule, which contains a 
poly-A tail but no 5’ cap. The RNA genome is approximately 5.3 to 5.5 
megadaltons in size and serves as messenger RNA upon infection. RNA polymerase 
is not associated with the virion and the first step in the viral replicative cycle is 
translation, meaning the genome is intrinsically infectious.
Figure 1 shows the postulated organization of the Hepatitis A virus genome 
based on the nomenclature of Rueckert and Wimmer (77). The genome is divided 
into three regions: P I, P2, and P3. The PI proteins (1A, IB, 1C, ID) constitute 
the structural capsid proteins VP4, VP2, VP3, and VP1 respectively. The P2 
proteins (2A, 2B, 2C) encode for a viral protease which cleaves between the PI and 
P2 regions, a second protein of unknown function, and a third protein presumptively 
associated to anchoring the VPg terminal peptide to the viral genome. The P3 
region (3A, 3B, 3C, 3D) encodes for a protein, which functions as a presumptive 
donor for the VPg terminal peptide, the VPg peptide, a second viral protease, and a 
viral polymerase, respectively. The latter two regions, P2 and P3, orchestrate the 
replication and processing of viral peptides during the infection cycle.
Replication of the Hepatitis A virus follows the scheme postulated for the 
Picomaviridae family of viruses. Figures 2a, 2b, and 2c picture the Picomaviral 
infection cycle. Briefly, HAV attaches to a receptor on the cell surface which has 
not been fully characterized. The tissue in which HAV replicates has been identified 
by immunofluorescent staining with anti-HAV specific antibodies, to be the 
cytoplasm of hepatocytes as the sole site for viral replication. However HAV 
receptor sites present in the gastrointestinal tract seem likely due to the susceptibility 
to HAV infection by the oral route. Target cell attachment is followed by 
penetration of the virion into the cell cytoplasm by viropexis (endocytosis), at which 
time virus uncoating starts. Release of viral RNA is a relatively slow process, 
taking approximately 12 hours, due to the high affinity between the capsid and viral 
RNA. Once uncoating is completed, the viral RNA, now free in the cell cytoplasm, 
serves as messenger RNA and translation begins. The virion RNA is translated in 
one large open reading frame yielding a polyprotein which is processed by viral 
proteases. Polyprotein processing generates a group of viral structural proteins (PI) 
and a second group of nonstructural proteins (P2, P3). Simultaneously, virion RNA 
is transcribed generating negative stranded copies of the viral genome which serve as 
templates for positive strand synthesis. The high affinity exhibited by accumulating 
procapsids for positive stranded RNA results in encapsidation of the majority of the 
positive strand copies of the viral genome producing assembled mature virions.
Hepatitis A virus infections exhibit an incubation period which ranges from 
15 to 50 days with an average of 30 days. Although a high number of HAV
4
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Figure 1: Structure of the Picomaviral RNA and proposed model for the genetic 
organization of the HAV polyprotein based on the 434 cleavage pattern. 
P I, P2, and P3 refer to precursor proteins that are cleaved by virus 
encoded proteases. VPg (5’ viral terminal peptide), ntr (nontranslated 
region), VP (viral capsid protein), AAAn (poly(A) tract). (Nomenclature 
from the European Study Group on the Molecular Biology of 
Picomaviruses, 1983).
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Figure 2A: Attachment of the virion to receptors involved in the delivery of the 
viral genome to the cells cytoplasm. The delivery and uncoating 
processes are not completely understood. The viral RNA utilizes the 
protein synthesizing machinery from the hepatocyte to form 
polyribosomes generating a polyprotein that will be processed in the 
precursor proteins PI, P2, and P3.
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Figure 2B: Proteolytic processing of the coat precursor protein (PI) forming an 
immature protomer (5S) composed of the aggregated VPO, VP1, and 
VP3, which later assemble into pentamers (12-14S). Processing of the 
P2 and P3 regions generates the virion proteins necessary for RNA 
synthesis through a complementary minus-stranded RNA intermediate.
7
III. PICORNAVIRAL INFECTION CYCLE











III = poly (A)
4 ^ 0  = ribosom e 
O  =  replicase
Figure 2C: Synthesis of (+ ) RNA through a multistranded replicative intermediate 
associated with the smooth endoplasmic reticulum. The (+ ) RNA pool 
is used for translation, synthesis of additional (-) RNA and ultimately 
packaged into virions. Upon packaging the infectious virions (150- 
160S) undergo "maturation cleavage" where the VPO peptide is cleaved 
to form the four chain subunits VP4, 2, 3, and 1. Virions are released 
after lysis of the host cell.
infections are subclinical, when signs of acute infection are present, the onset of the 
prodromal or preicteric phase is characterized by an abrupt transition from wellness 
to a flu-like state. This transition which occurs within a 24 hour period manifests 
with fever, chills, fatigue, malaise, myalgia, anorexia, nausea, and vomiting. The 
preicteric phase is followed by the icteric phase which is marked by the appearance 
of dark urine, bilirubinuria, an excess of bilirubin in the urine. Jaundice is evident 
within 24 hours following bilirubinuria and lasts for one to two weeks. The yellow 
sclerae observed during this period is suggestive of serum bilirubin levels > 3  mg%. 
Although fever subsides by this stage, the liver becomes enlarged and tender to 
percussion of the right upper quadrant of the abdomen. The histopathologic lesions 
present during the acute phase of the disease are indistinguishable from lesions 
present during hepatitis infections induced by viruses other than Hepatitis A virus. 
Liver function tests are useful to confirm acute hepatitis. In addition to bilirubin 
levels, serum aspartate aminotransferase (AST, SGOT), alanine aminotransferase 
(ALT, SGPT), and alkaline phosphatase levels are monitored. Each 
aminotransferase shows rapid elevation during the incubation period. As the disease 
course progresses the symptoms and case presentation become more characteristic of 
Hepatitis A infection, specifically during the later stages of the infection. Liver 
biopsy reveals hepatocyte necrosis, mononuclear cell infiltration and cholestasis.
The acute infection lasts 3 to 4 weeks with variable severity dependent upon factors 
such as age, sex, and general health. The virus is detectable in feces during the 
preicteric and early icteric phases and then is no longer detectable shortly after the
onset of clinical manifestations. Treatment of benign acute viral hepatitis A is 
basically supportive and directed toward maintaining patient comfort where 
hospitalization is not ordinarily indicated. The liver appears normal following 
recovery from the infection.
The events which produce liver cell destruction are not well understood since 
no evidence for direct hepatocyte destruction by the intracellular virus has been 
established. This observation correlates with the lack of cytopathogenicity of HAV 
in cell culture. Investigators have identified HAV-specific T-lymphocyte mediated 
cytotoxicity and natural killer cell activity as the primary interactions leading to 
hepatocellular injury associated with this infection (87, 28).
Hepatitis A infection or acute hepatitis is endemic worldwide. Although the 
incidence of Hepatitis A infections do not show a clear seasonal distribution or 
pattern, where seasonality is observed the annual peaks cluster during the fall and 
winter months (75). Mortality rates for acute hepatitis are low (<  1%), and are 
usually associated with cases of fulminant hepatitis, a rare complication observed in 
hospitalized cases. Fulminant hepatitis manifests as a deep jaundice, drowsiness, 
encephalopathy, and coma with a meantime progression from the onset of 
bilirubinuria to encephalopathy of 7 days, and death in 13 days. The epidemiology 
of the Hepatitis A virus is influenced by the level of sanitation and personal hygiene 
practiced especially in third-world nations. In these countries the infection usually 
occurs early in life in an asymptomatic state which provides for life-long immunity. 
Outbreaks of hepatitis A in developed countries are usually sporadic, and confined to
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specific groups within the population, such as children, daycare center personnel, 
travelers, homosexual men, and intravenous drug users (75). In developed countries 
which maintain high sanitation standards HAV infections usually occur in the adult 
population, with little evidence for the subclinical childhood experience.
Since signs and symptoms exhibited during the icteric phase of Hepatitis A 
infection cannot differentiate among the spectrum of possible etiological agents, 
definitive diagnosis is reliant upon specific laboratory tests. Diagnosis of Hepatitis 
A infection is made by detection of antibodies to HAV. Immunoglobulin M-specific 
anti-HAV antibody levels rise rapidly in concert with the development of symptoms. 
The titer increases rapidly for 4 to 6 weeks and then declines to nondetectable levels 
over the next 3 to 6 months. Demonstration of anti-HAV IgM suggests current or 
recent infection. Anti-HAV immunoglobulin G follows the IgM response reaching 
peak titers for a period of 3 to 8 months. The presence of anti-HAV IgG indicates 
past infection and will provide life-long immunity.
CHAPTER I
PRODUCTION OF MONOCLONAL AND POLYCLONAL ANTIBODIES 




Monoclonal antibody technology, a tool where an antibody of a particular 
specificity can be generated, selected for, and produced in large quantity, has had an 
enormous impact in a wide variety of research and clinical areas. The technique, 
introduced by George Kohler and Cesar Milstein in 1975 (47), exploited the 
consequence of cell fusion or somatic cell hybridization between a normal antibody- 
producing B cell and a myeloma cell line. B-cell : myeloma cell hybridization 
generated an immortalized antibody-producing cell line of monoclonal origin.
Among the most common applications that monoclonal antibodies provide are, (i) 
identification of cell surface markers, (ii) immunodiagnostics, (iii) tumor-specific 
diagnosis and therapy, (iv) analysis of cell surfaces, (v) analysis of secreted 
molecules, and (vi) catalysts for chemical reactions, among others. Another 
important application for monoclonal antibodies has been in the identification of 
antigenic sites or epitope mapping. The identification of these sites has aided in 
identification of targets for detection, diagnosis, immunization and vaccination, and 
also for antigen specific immunosuppression. Identification of antigenic sites applied 
to the surface of viruses has been useful for identification of neutralization sites, for 
serotyping, elucidation of antigenic variation, and development of subunit vaccines 
based on identification of relevant epitopes.
Neutralizing monoclonal antibodies have been applied successfully in the 
identification of antigenic sites in the viral capsid of HAV (54, 67, 82). Detection
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of neutralization escape mutants has also aided in the identification of mutations 
associated with virulence and/or resistance to neutralization, elucidation of the 
molecular nature and mechanisms associated with target cell binding and 
pathogenicity. The availability of neutralizing monoclonal antibodies against HAV 
are currently controlled by a few private sources and access to them is limited. Ping 
et al. (67) utilized available MAbs from five sources to elucidate the 
immunodominant epitopes in the viral capsid peptide VP3. The five sources of anti- 
HAV hybridomas used were obtained from; the Commonwealth Serum Institute, 
Melbourne, Australia, Middlesex Hospital in London, Merck Institute for 
Therapeutic Research, West Point, PA., Clonatec, Paris, and Sichuan Health and 
Anti-Epidemic Station in Chengdu City, Peoples Republic of China.
The production of monoclonal antibodies against the HM175 strain of the 
Hepatitis A virus was pursued in this investigation to provide continuous access to 
HAV-specific MAb’s.
MATERIALS AND METHODS
Viral strain. The HM175 strain of the Hepatitis A virus was used as the 
immunogen for the generation of monoclonal antibodies. Formalin inactivated virus 
was kindly provided by Dr. Mark D. Sobsey (University of North Carolina, Chapel 
Hill, NC).
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Immunization of Experimental Animals. Female Balb/C mice were used as spleen 
donors for the production of hybridomas. The animals were immunized by two 
different methods. In the first schedule the animals were immunized by 
intraperitoneal injection with formalin preserved Hepatitis A virus. Six 
intraperitoneal injections were administered with increasing doses at weekly intervals 
with 4 x 108 to 2 x 109 virions. The spleens were harvested nine days following the 
last injection. In the second schedule the animals were immunized intraperitoneally 
with 1010 virion particles emulsified in a Freunds Complete Adjuvant. After a 
period of 30 days the animals were boosted with 10'° virion particles emulsified in 
Freunds Incomplete Adjuvant. Thirty days later and four to three days before the 
spleens were harvested, the animals were boosted intraperitoneally with the same 
number of viral particles suspended in saline suspension.
Polyvalent antiserum was produced in New Zealand White rabbits immunized 
with intact Hepatitis A virions. A rectangular area on the back of the animal was 
depilated 24 hours before immunization. The animals were anesthetized with a 
single injection which contained 15 mg of Rompum (Xylazine hydrochloride) 
(Haver-Mobay Corp., Shawnee, Kansas) and 100 mg of Ketaset (Ketamine 
hydrochloride) (Bristol Laboratories, Syracuse, NY). A total of 5.6 x 1010 virions 
in a volume of 1 ml of sterile phosphate buffer saline were emulsified with an equal 
volume of a Freunds Complete adjuvant. The emulsion was injected intradermally 
in 15 - 20 sites on the shaved dermis of the rabbits, approximately 0.1 ml per site.
A test bleed was collected on day 30 and the animal was boosted with 5.6 x 1010
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virions emulsified in a Freunds Incomplete Adjuvant. Before blood collection and 
the boost injection, the animals were injected with one dose (0.1 ml/Kg body 
weight) of the muscle relaxer PromAce (Acepromazine Maleate) (Fort Dodge 
Laboratories Inc., Fort Dodge, Iowa). The adjuvant emulsion was injected in 0.5 
ml volumes once in each hindquarter and once on each side of the neck of the 
animal. Test bleeds were obtained every two weeks after day 30 and the animals 
were exsanguinated after the fourth test bleed (day 90). The test blood sample 
collected in sterile glass tubes were allowed to stand at room temperature for one 
hour to allow clot formation. The clot was separated from the sides of the glass 
tube and placed in the refrigerator overnight to permit clot retraction. The next day 
the serum was removed and centrifuged at 400 x g for 15 min. to sediment cells.
The clarified serum was aliquoted in sterile cryovials and stored at -20°C until 
needed.
Spleen Cell-Myeloma Cell Fusion. Hybridomas were produced by the method of 
Kohler and Milstein (47) and modified by Oi and Herzenberg (61). The spleens 
were removed aseptically from immunized mice and washed twice in Calcium- 
Magnesium free Hanks Balanced Salt solution (CMF-HBSS, 0.4 g/1 KC1, 0.06 g//l 
KH2P 0 4, 8 g/1 NaCl, 0.09 g/1 Na2HP047H20 , 1 g/1 C6H120 6, 0.35 g/1 NaHC03).
The spleens were transferred to a sterile Petri dish, cut in half, and reduced to a 
single cell suspension by compressing each spleen half in 2 to 5 ml of CMF-HBSS 
with surgical forceps. The spleen cell suspension was transferred to a sterile
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centrifuge tube (Corning Incorporated, Corning, NY) and the large cell clumps were 
allowed to settle before the cell suspension was decanted to a second centrifuge tube. 
The immune spleen cells were sedimented and washed twice in CMF-HBSS and a 
third time in serum-free medium (RPMI-1640 (Difco Laboratories, Detroit, MI),
15% Fetal Bovine Serum (Gibco BRL, Rockville, Md), 1% 200 mM L-glutamine,
1 % non-essential amino acids, 50 IU/ml Penicillin G, 50 lU/ml Streptomycin Sulfate 
(Sigma Chemical Co., St. Louis, Mo.)). The washed spleen cells were resuspended 
in 10 ml of serum-free RPMI and then enumerated in a hemocytometer. A 
suspension of 108 spleen cells was mixed with the SP2/0 myeloma cells in ratios 
that varied from 4:1 to 1:1 spleen to myeloma cells. The cells were centrifuged 
immediately upon mixing in a sterile 50 ml plastic conical centrifuge tube at 400 x g 
for 10 min at room temperature. The tube containing the cell pellet was placed in a 
water bath at 37°C to maintain a constant temperature during the subsequent steps. 
One ml of 50% (v/v) polyethylene glycol in 75 mM HEPES buffer (PEG 1500, 
Boehringer Mannheim Biochemicals, Indianapolis IN), was added dropwise over a 
one minute period with continuous stirring. Following the addition of polyethylene 
glycol the mixture was stirred for an additional minute. Next, the PEG was diluted 
by the addition of 1 ml of serum-free medium followed by a one minute incubation 
period, 2 ml of serum-free medium followed by a two minute incubation, 4 ml of 
medium followed by a four minute incubation, and finally 8 ml of serum-free 
medium. The cells were centrifuged at 200 x g for 10 min and the supernatant fluid 
was removed and discarded. The cell pellet was resuspended in 24 ml of
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RPMI/15% FBS + antibiotics to give a cell density of 3 x 10s spleen cells/ml. 
Approximately 0.1 ml aliquots were transferred to each well of a 96-well tissue 
culture plate (Corning Glass Works, Coming, N.Y.), which contained 0.1 ml of a 2 
X 106 cell/ml thymocyte cell suspension which served as the feeder cell layer to the 
developing hybridomas. The plates were incubated at 37°C in a 7% C 02-in air 
incubator.
On each of the five days following fusion, the developing hybridomas in each 
well were fed 0.1 ml of RPMI-1640-HT medium supplemented with 4 x 10-5 M 
aminopterin (Hypoxanthine-Aminopterin-Thymidine medium). One tenth milliliter 
was removed from each well prior to the addition of fresh media. On the 6th, 7th, 
and 8th day the developing hybridomas were fed 0.1 ml of HT medium, to dilute 
the aminopterin concentration in each well. Thereafter the cells were fed with HT 
medium every 3 to 4 days while growth of hybridomas was monitored. Supernatant 
fluid removed from wells which contained hybridomas were assayed for antibody 
secretion.
Assay for Hybridomas Secreting anti-HAV Immunoglobulin. Two
enzyme linked immunosorbent assays (ELISA), which used a second antibody 
labelled with alkaline phosphatase, were used to detect antibody secreting 
hybridomas with specificity for the Hepatitis A virus.
The first ELISA protocol was designed to identify wells which contained 
hybridomas actively secreting antibody without regard for HAY specificity. When
18
MAb-secreting hybridomas were identified they were retested by the second antigen- 
specific ELISA in which the antibody-secreting hybridomas were tested against 
Hepatitis A virus.
Ninety-six well Immulon II Microtiter plates (Dynatech Laboratories Inc., 
Alexandria, Va.) were used for each ELISA. For the first ELISA protocol, goat 
anti-mouse immunoglobulins (IgA, IgM, IgG) the capture antibody was diluted in 
carbonate coating buffer (0.6 M NaHCO3/0.6 M Na2C 03, pH 9.6), (Cappel/Organon 
Teknika Corp., West Chester,Pa.). Four micrograms of capture-antibody protein in 
50 jx\ was distributed to each well and the ELISA plates were incubated at 4°C 
overnight. Following incubation the coating buffer was removed and 200 ^1 of 
blocking buffer (0.05 M Tris-HCl, pH 7.2, 0.001 M EDTA, 0.15 M NaCl, 2%
BSA, 10% fetal bovine serum), was added to each well and the blocking step was 
carried at room temperature for 45 min. After incubation the plates were washed 
twice with 200 /xl of TEN buffer (0.05 M Tris-HCl, pH 7.2, 0.001 M EDTA, 0.15 
M NaCl, 0.05% Tween 20). Next, 50 tx\ of tissue culture supernatant fluid removed 
from wells which contained developing hybridomas were added to each well and 
incubated for one hour on a rotary platform. The plates were washed six times and 
50 (x\ of goat-anti-mouse Ig-alkaline-phosphatase enzyme conjugate (Cappel/Organon 
Teknika Corp., West Chester, Pa.), diluted in 10% FBS, 0.05% Tween 20 in TEN 
were added to each well. The plates were incubated for 45 min at room temperature 
and washed six times with TEN, 0.05% Tween 20. Finally, 200 fj.\ of the substrate 
para-nitrophenyl phosphate (Sigma Chemical Co., St. Louis, Mo.) was added to
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each well. The substrate was dissolved at a 1 mg/ml concentration in 
diethanolamine buffer (9.7% (v/v) diethanolamine, 0.02% (w/v) NaN3, 0.01%
MgCl2 6H20 , pH 9.8). The plates were incubated in the dark at 37°C for 15 min to 
1 hour and color development was monitored in the control wells. The enzyme- 
substrate reaction was stopped by the addition of 50 /ul of 3N NaOH per well. 
Absorbance was measured at 500 nm using a Bio-Tek EIA Reader (Bio-Tek 
Instruments Inc.).
The second ELISA, an antigen specific immunoassay, was run to identify 
those clones that tested positive for antibody secretion, for specificity against the 
Hepatitis A virus. Fifty microliter aliquots containing approximately 2 x 106 
Hepatitis A virions diluted in sterile phosphate buffered saline (0.067 M PBS, pH 
7.2) were deposited into each well of a ninety-six well Immulon II microtiter plate. 
The plates were incubated at 4°C overnight and then 100 fd of a 0.5% 
glutaraldehyde solution in PBS was added slowly to each well. The plates were 
incubated at room temperature for an additional 30 minutes, after which the fluid 
was removed by inverting and then shaking the plates. Each well was washed one 
time with 200 /d of PBS and the remaining steps were essentially the same as those 
described above for the antigen capture ELISA. Following addition of substrate, the 
plates were incubated in the dark at 37°C for 1 hour and then A500 was determined. 
Clones which tested positive by the antigen-specific ELISA were cloned through two 
limiting dilution steps by the method described by Oi and Herzenberg (61). The 
HAV-specific hybridomas were isotyped by a gel immunodiffusion assay (The
20
Binding Site Inc., San Diego, CA), to determine immunoglobulin class secreted 
which dictated the course of MAb purification. Selected hybridomas were expanded 
in 75 cm2 tissue culture flasks and the cells were maintained in logarithmic growth 
phase with a viability of 90% or higher. The hybridoma cells were concentrated by 
centrifugation and resuspended in cold medium (RPMI-HT-20% FCS, 10% 
dimethylsulfoxide) to a cell density of 2-5 x 106 cells/ml. The resuspended cells 
were then aliquoted in sterile 2 ml vials (Sarsted Inc., Princeton, NJ), frozen under 
liquid nitrogen and stored until needed.
Concentration of Monoclonal Antibodies: Hybridoma culture supernatant 
fluids were collected and the immunoglobulin fractions were purified and 
concentrated by affinity chromatography. A Sepharose-Protein A matrix, or a 
Sepharose-Anti-Mu matrix (Sigma Chemical Co., St. Louis, Mo.), were used to 
affinity purify IgG and IgM from hybridoma supernatant fluid respectively.
Following elution from column matrices the immunoglobulins were dialyzed against 
borate buffered saline (pH 8.3). To achieve hundredfold concentration, the 
recovered immunoglobulin eluates were concentrated using an Amicon ultrafiltration 
membrane (Amicon Corporation, Lexington, Massachusetts) with a molecular weight 
cutoff of 50,000 Daltons. Antibody protein concentration was determined by the 
Bicinchoninic Acid Protein Assay (Pierce Chemical Co., Rockford, II.).
Monoclonal antibodies purified and concentrated to this point were tested for 
specificity against the Hepatitis A virus by a Capture Antibody Assay, Antibody
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Competition Assay, and a Virus Neutralization Assay (laboratory of Dr. Mark D. 
Sobsey at the University of North Carolina, in Chapel Hill).
Capture Antibody Radioimmunoassay : Anti-HAV activity was assayed by 
a modification of the microtiter solid phase radioimmunoassay described by Purcell 
et al. (73). Ninety-six well polyvinyl microtiter plates (Cooke Laboratories, 
Alexandria, Va.) were coated with 75 (A of the test MAb at different antibody 
protein concentrations. A HAV capture antibody standard (1:800 Feinstone anti- 
HAV) was included as the positive control. Plates were incubated overnight at 4°C 
in a humidified chamber. After coating the volume was aspirated and the wells 
were rinsed twice with phosphate buffered saline-sodium azide (0.067 M PBS - 
0.01% NaN3), and aspirated to dryness. The plates were then coated with 250 jal of 
PBS - 2% BSA - 0.01% NaN3 and incubated overnight at 4°C in a humidified 
chamber. Following the blocking step the supernatant fluid was aspirated and the 
wells were rinsed three times with the PBS-sodium azide. Seventy-five microliters 
of an HAV suspension were added to each test well and the plates were incubated 
for 1 to 2 days at 4°C. Negative control wells received the same volume of PBS- 
azide, instead of the virus suspension. After incubation the volume was aspirated 
and the wells were rinsed five times with PBS-azide with no incubation. Next, 50 
fi\ of 125I - labelled anti-HAV was added to each well. The plates were incubated 
for 4-6 hours at 37°C in a humidified chamber. The labelled antibody was then 
aspirated and the plates were washed five times with the PBS-azide. Individual
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wells were removed from the plate and placed in clean 12 x 75 mm gamma counting 
tubes. Quantitation of residual (bound) radioactivity was performed with a 
Beckman 5500 gamma counter with a 0.5 min count interval per sample well. The 
radioactive counts per minute detected in each test well were divided by the mean 
residual cpm in the negative control well. The quotient was expressed as 
positive/negative (P/N) value. P/N values were calculated as follows;
[P/N=(average counts per minute - background)/(negative well counts per minute - 
background)]. P/N values greater than 2.1 were considered as positive for the 
presence of HAV captured by the test antibody.
Antibody Competition Radioimmunoassay : A modification of the capture
radioimmunoassay described previously was employed to measure anti-HAV activity 
in a competition assay against a standard anti-HAV antibody (Feinstone fractionated 
human anti-HAV antibody). Microtiter plates were precoated with 75 /x 1 of the 
standard antibody. The plates were incubated for 4 hours in a humidified chamber 
at 4°C. Plates were washed twice with PBS and 250 ^1 of blocking buffer PBS-1% 
BSA were added. The plates were incubated in the humidified chamber at 4°C 
overnight. After incubation the plates were washed twice with PBS followed by 25 
fx 1 of HAV antigen. The plates were incubated overnight at 4°C in the humidified 
chamber. Next, the wells were aspirated and washed five times with PBS. After 
washing, 50 (x\ of decimal dilutions of test MAb were added to each well and 
incubated at 37°C for 1 hour. Next, 50 /xl of I25I anti-HAV IgG were added to
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each well, incubated for at least 4 hours at 37°C, washed five times with PBS and 
the wells were removed for quantitation of residual radioactivity in a gamma counter 
as mentioned above.
Viral Neutralization Assay : Cell monolayers of FRhK-4 cells (fetal
Rhesus monkey kidney cell line) were used to assess the MAb for neutralization 
activity. Aliquots of 0.25 ml volumes of HAV antigen suspension titered at 500 
PFU/ml were mixed with an equal volume of MAb dilutions in Eagles MEM (Difco 
Laboratories, Detroit, Mi). The suspensions were incubated at 37°C for 30 min. 
Following incubation, 0.2 ml volumes of the virus-MAb suspension were inoculated 
onto the FRhK-4 cell monolayers in duplicate. Plates were incubated at 37°C in a 
7 % C 02-in air incubator and monitored for cytopathic effect. Positive control plates 
were inoculated with 0.2 ml of a previously incubated suspension of 0.25 ml of 
HAV which had been mixed with 0.25 ml of MEM as diluent. Negative control 
plates were inoculated with 0.2 ml of MEM diluent. A standard neutralizing 
antibody was also used for negative controls.
RESULTS
A total of 12 anti-HAV secreting hybridomas were generated from three 
fusion experiments. Each clone was positive for immunoglobulin secretion and anti- 
HAV specificity as determined by the immunoassays developed for this purpose.
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Table 1 shows the immunoglobulin isotype secreted by each hybridoma determined 
by a gel diffusion assay (The Binding Site, San Diego, CA), and by an enzyme 
immunoassay (Promega, Madison, WI). The clones P2-H8 and P1-G4 showed 
inconclusive results by gel diffusion due to faint precipitation bands and low color 
development by immunoassay, which was indicative of low MAb synthesis and 
secretion levels.
Tissue culture supernatant fluid was collected from each clone and the MAb 
was concentrated following affinity chromatography on either a Protein-A Sepharose 
matrix or an anti-Mu chain Sepharose matrix. Aliquots of each MAb were tested in
the laboratory of Dr. Mark D. Sobsey (University of North Carolina, Chapel Hill),
by a competitive radioimmunoassay against an anti-HAV antibody, assessed as a 
capture antibody for the HM-175 strain of HAV, and tested by in-vitro viral 
neutralization assay using a FRhK-4 cell line. Of the 12 clones tested only
hybridoma P2-G9 showed neutralizing activity against the Hepatitis A virus. The
results obtained from the competitive RIA and the antigen capture assay revealed 
inconclusive results due to constant high background counts from the 125I-labelled 
anti-HAV antibody used in both assays. After repeated efforts to titer the labelled 
antibody and assess the efficiency of the blocking steps for the assay no significant 
improvement was obtained. However, the screening of monoclonal antibodies 
showed clone P2-G9 secreted an antibody which exhibited neutralizing activity.
The findings obtained from viral neutralization assays identified one possible 
problem, which involved immunogen dose utilized to immunize the mice. Mice
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were immunized with HAV doses which ranged from 2 x 108 virions to 1 x 1010 
virions, concentrations equivalent to 2 micrograms of virions and 1.16 micrograms 
of viral protein. This approximation is based on a 68.4% protein content estimated 
for Poliovirus (76). These doses have been reported as suboptimal by MacGregor et 
al.(54) and Hughes et al.(40). The first group assessed different immunization 
schedules and total virus protein concentrations which ranged from 4 to 6 
micrograms incorporated into Freunds complete adjuvant, whereas the second group 
used a single immunization dose of 5 micrograms of total viral protein followed by a
3.5 fxg dose of purified HAV as a boost immunization prior to fusion experiments. 
Utilization of a sub-optimal immunogen dose could account for the absence of 
neutralization activity for 11 of 12 clones generated and also for the low 
neutralization titer for MAb P2-G9.
A rabbit was immunized for production of polyvalent anti-HAV serum. 
Because limited quantities of HAV were available and in order to preserve 
immunogen a multiple injection-low immunogen dose approach was followed. This 
immunization protocol has been reported to be successful when quantities of 
immunogen are limited and high antibody titer is required (R.J. Siebeling, personal 
communication). The antiserum raised here will be of value for the next two 
sections of the investigation reported since the antiserum raised against intact HA 
virions could be applied in the identification of expressed fusion peptides by Western 
blot analysis and also could constitute an alternative capture antibody for the 
detection assay discussed in the second chapter of this dissertation.
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TABLE 1: Hybridomas generated against the Hepatitis A virus (HM 175 strain) 
and MAb immunoglobulin isotype defined by gel diffusion 
and enzyme linked immunoassay.
CLONE IMMUNOGLOBULIN
DESIGNATION ISOTYPE
P2 - F2 IgG
PI - C4 unknown
P2 - F4 IgG
P2 - H8 unknown
P2 - G9 IgG
PI - B7 IgG
PI - E ll IgG
P2 - G5 IgM
P2 - G il IgM
P4 - B8 IgM
P6 - B5 IgM
PI - C4a IgM
27
DISCUSSION
The development of monoclonal antibodies against the Hepatitis A virus has 
launched a research effort to characterize the immunodominant antigenic sites of the 
HA viral capsid. With the aid of antibody imaging and the study of neutralization 
escape mutants, it has been possible to elucidate an absence of antigenic variation 
for HAV where a single antigenic specificity is reported (78). In addition to these 
studies, identification of one major antigenic site in the virion capsid has been 
reported (40, 78), although this topic is still under dispute (65, 39, 31). Antibodies 
specific for the virion provide an important serological tool for development of 
methods to detect and identify this enteric pathogen, however this has not come 
without difficulty since the generation of large quantities of HAV has hampered the 
generation of sufficient immunogen for research manipulations.
In the present research, we set out to develop the serological components 
necessary for the entire research project, which at the same time will allow 
independence from the known, but restricted MAb sources. The major obstacle to 
meeting the objectives was the limited availability of virus for immunization and for 
use in the developed immunoassays. The paucity of HAV may have influenced 
development of neutralizing MAb’s where 1 out of 12 hybridomas showed 
neutralization activity. For one mouse immunization scheme, increasing doses from 
2 x 108 up to 1 x 1010 virions, were injected intraperitoneally. Upon calculation, it 
was estimated that the inocula used contained virus numbers below the immunogenic
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doses previously reported (54, 40). In the second immunization regime, adjuvants 
were used. No neutralizing MAb activity was obtained from subsequent fusions and 
the majority of hybridomas generated secreted IgM immunoglobulin MAb. These 
findings supported the low-immunogen interpretation since the second adjuvant HAV 
boost seemed to elicit a primary immune response instead of promoting and 
prolonging a secondary immune response from the initial immunization with the 
complete adjuvant. Low incidence of neutralizing MAb activity had been reported 
previously by MacGregor et al. (54), where their investigation produced four anti- 
HAV MAb’s which showed incomplete or marginal neutralization activity against 
cell-culture derived HAV. They suggested a requirement for prolonged incubation 
periods with antibody before total neutralization activity could be achieved and 
assayed.
In summary, to effectively generate an optimal immune response it will be 
necessary to increase the immunogen doses to levels at the 10 microgram range or 
above independent of the immunization method, and immunize several animals to 
evaluate variability in the immune responses among individual animals. Utilization 
of optimal HAV doses may permit antigen persistence which may permit the 
consequent maturation of antibody affinity due to constant exposure to optimal 
amounts of the immunogen.
For the assessment of neutralization activity, longer incubation periods at 
room temperature or 37°C followed by overnight incubation at 4°C should be 
employed as recommended by McGregor’s et al. (54). The rationale behind this
recommendation is to closer simulate the attachment and penetration events that take 
place when the virus interacts with the available surface receptors on the target cell 
in vivo. Since this is a still poorly understood sequence of events it will be 
necessary to investigate in more detail the characteristics and duration of this early 
event in the infectious process of this virus.
CHAPTER n





Patterns of Hepatitis A disease reflect the standards of hygiene and sanitation 
of the specific population, therefore exhibiting a wide variability between population 
groups. The exact prevalence of the disease remains uncertain basically due to 
different forms of surveillance adopted by different countries and the large number 
of subclinical infections predominantly in the children population. For Hepatitis A 
the most common route for transmission is the fecal-oral route. This route of 
transmission predominates between person to person contacts, where young children 
account for a majority of the cases. Water borne transmission has also been 
reported as a result of sewage contamination of water supplies (37, 80). Food-borne 
hepatitis A is mainly associated with the consumption of shellfish (oysters, clams, 
mussels), harvested from waters contaminated with human feces (sewage).
However, outbreaks of food-borne hepatitis A have also been associated to food 
items different from shellfish, as a result of contamination by a food handler (53). 
Oysters are often associated with HAV transmission since they obtain oxygen and 
feed by filtration of surrounding water, and will concentrate bacterial and viral 
pathogens that may be present (1, 20, 34, 56, 90). Since oysters are often eaten 
raw, they become a potent inoculum for this viral pathogen. Food-borne HAV 
infections associated with food items other than shellfish are usually caused by food 
handlers with poor personal hygiene at the stage where virus is being shed (53).
The long incubation period, before the onset of noticeable symptoms makes it
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difficult to track down the source of HAV since the food handlers may no longer 
show symptoms, or recall their infection.
Monitoring environmental waters for potential sources of seafood-associated 
hepatitis A for epidemiological reasons has proven difficult due to a combination of 
factors. First, there are no viral indicators in place to predict viral pathogen 
contamination. The current public health safety for shellfish and shellfish-harvesting 
waters in the U.S. are judged by bacteriological standards. Under these regulations, 
the most probable number of coliforms in shell-fishing waters should not exceed 70 
per 100 ml and no more than 10% of the samples examined should exceed 230 
coliforms per 100 ml in areas approved for harvesting. For shellfish, these 
standards specify that processed meat should not possess more than 230 fecal 
coliforms per 100 grams (93). Previous reports (32, 35, 68) have shown that these 
bacteriological standards are inadequate to evaluate shellfish growing areas for the 
presence of viral pathogens, since hepatitis outbreaks have been linked to harvesting 
areas meeting the bacteriological specifications set by the National Shellfish 
Sanitation Program (38). The second complication is the sources of supply, where 
in some instances there are few or no regulations over the cultivation, harvest, 
transport and processing of this product.
During an epidemic of hepatitis A associated with consumption of raw 
shellfish, Mele et al. (58) discussed several aspects that lead to an increase in 
confirmed cases of the viral infection. The study revealed that during an epidemic 
period in Italy, shellfish being sold were available from two sources. In the first
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source, shellfish was harvested from waters adjacent to sewage outfalls therefore 
posing a health hazard, whereas the second source of shellfish was from a major 
depuration plant where the shellfish were cleansed and sealed in plastic bags for 
retail. This situation points specifically to the lack of governmental regulation and 
policing of unlicensed retailers which are more likely to evade or ignore food safety 
and public health regulations. In addition to the potential for viral contamination at 
the point of harvest, the case study reported potentially hazardous handling practices 
during which cleansed shellfish were re-exposed to sewage contaminated seawater 
when the product was sprinkled with the purpose of freshening the appearance of the 
display. This practice has proven to account for the contamination of seafood with 
bacterial pathogens although no viral contamination from this particular practice has 
been. Again, the absence of methods to monitor water for viral contamination 
makes it difficult to specifically identify the source of contamination and therefore 
the virus source can not be tracked to the commercially supervised and depurated 
process or to shellfish harvested from the sewage contaminated waters.
Documented outbreaks of acute hepatitis associated with consumption of 
shellfish emphasizes the need for specific and sensitive methods to monitor the 
shellfish growing environment and shellfish. A review and definition of regulatory 
policy regarding viral pollution in shellfish products intended for human 
consumption should be addressed. One compelling argument in favor of a more 
definitive policy was revealed in a study by Gerba et al. (32, 35). They reported 
detection of Enteroviruses in waters which met acceptable bacteriological standards
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for shellfish harvesting, and in oyster samples collected from these same approved 
harvesting areas even on occasions where the MPN for total and fecal coliforms 
were as low as 3/100 ml of water (35).
Several different approaches have been used to detect Hepatitis A virus in 
clinical and/or environmental specimens. Humphrey et al. (41) used solid phase 
immune electron microscopy (SPIEM) to detect Hepatitis A and non-A non-B 
hepatitis (Hepatitis E) virus particles in stool and cell culture extracts. Solid phase 
immune electron microcopy (SPIEM) for Hepatitis A showed a sensitivity of 105 
radioimmunofocus units (RFU) for tissue culture preparations. Non-specific 
aggregation of antigen was reported in the 10% stool preparations studied.
DNA and RNA probe technology has been applied to the detection of 
Enteroviruses. Oren et al. (62) made use of molecular hybridization with a HAV- 
complementary DNA probe to detect HAV RNA in the serum of patients during the 
prodromal and early icteric phases of the HAV infection. Although the sensitivity 
of the probe was not assessed, the specificity was compared to that of Abbot 
Laboratories radioimmunoassay to confirm HAV acute infection by detection of anti- 
HAV IgM antibodies. The cDNA-RNA hybridization detected HAV RNA in 23% 
of the serum samples positive in the Abbot radioimmunoassay which confirmed the 
existence of viremia during the prodromal or icteric phases of the infection. Shieh 
et al. (80) assessed the specificity and sensitivity of single stranded RNA probes 
and complementary DNA probes to detect HAV and other enteroviruses in seeded 
water samples. They reported greater sensitivity for the ssRNA probes compared to
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the cDNA probes, where as few as 500 to 1000 infectious units of purified virus 
were detected by ssRNA probe and the cDNA probes were approximately five-fold 
less sensitive.
Environmental samples contaminated with Enteroviruses are reported to have 
low titers of infectious particles, typically < 1-100 infectious particles per liter (7, 
48). This concentration is well below the sensitivity of ssRNA probes without prior 
amplification of viral genomic RNA. Shieh et al. (80) amplified the genomic viral 
RNA by cell culture propagation, however this step imposes a time constraint since 
the Hepatitis A virus is known for its poor and slow growth in cell culture which 
may require several weeks (13, 89, 92). On the other hand, propagation by tissue 
culture provides the advantage of establishing a direct correlation with particle 
infectivity. Although the authors considered application of the Polymerase Chain 
Reaction (PCR) to amplify the genomic RNA, it was Jansen et al. (44) who applied 
PCR in the development of a molecular epidemiological study of the Hepatitis A 
virus. Jansen et al. (44) utilized the specificity of the Polymerase Chain Reaction 
technique coupled with the immunospecificity of a capture antibody step. The anti- 
HAV capture antibody removed and isolated virions from fecal suspensions and PCR 
was used to selectively amplify genomic sequences unique to the Hepatitis A virus. 
When compared to techniques such as solid-phase radioimmunoassay or cDNA-RNA 
hybridization, two methods commonly used for detection in clinical samples, the 
antigen-capture-PCR (AC-PCR) assay showed greater sensitivity (44).
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One objective pursued in this research was to develop a method for detection 
HAV particles in shellfish. Ultimately, such a method could be of value to the 
shellfish industry which although not yet under governmental regulation like the 
poultry, beef, and pork industry, will soon become so by some federal agency (FDA 
or USDA), due to continuous pressure to ensure a safe and optimum seafood 
product for public consumption. Currently, identification of shellfish carrying 
enteroviruses, specifically HAV, is not possible within an acceptable time frame.
This is because of the already discussed difficulties associated with cell culture 
isolation of the virus which may require up to ten weeks (16), and may result in cell 
culture infections that produce no discernible cytopathic effect (16, 50). Current 
methodology applied to detection of HAV in infected monolayers include antigen 
detection by immunofluorescence, radioimmunoassay (5, 71), indirect quantitative 
plaque assays or radioimmunofocusing (50), and nucleic acid hybridization (86). 
Common denominators which detract from these methods are the time required to 
cultivate the virus, difficulty to isolate and purify nucleic acid material for detection, 
and the high cost associated with processing individual samples in either the clinical 
or the environmental setting.
Although AC-PCR offers advantages such as the antigen capture which 
reduces manipulation steps since isolation of viral nucleic acid is not necessary, 
automation of the PCR reaction, and exquisite sensitivity, the AC-PCR has 
important drawbacks. Problems associated to assay reproducibility, dedicated 
laboratory areas for specimen processing, PCR reagent preparation, and PCR
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amplification, need special attention for a technique such as AC-PCR. Processing of 
specimens that may not be compatible with PCR due to the presence of chemicals 
that may impede the enzymatic amplification of the target nucleic acid sequence 
constitutes another important factor. These mentioned considerations related to AC- 
PCR need to be weighted against the alternate methods for isolation and detection of 
the Hepatitis A Virus from clinical and/or environmental samples.
MATERIALS AND METHODS
Viral RNA Isolation: To assess the efficiency of the Polymerase Chain 
Reaction technique for the amplification of a specific viral sequence in the HAV, 
genomic RNA was isolated by the method of Chomczynski and Sacchi (12). In the 
extraction step 0.1 ml of virus suspension was mixed with 0.9 ml of solution D, (4 
M guanidine thiocyanate, 0.025 M sodium citrate [pH 7], 0.5% sarcosyl [N- 
Laurylsarcosine sodium salt], 0.1 M 2-mercaptoethanol). The following reagents 
were added to the virus - Solution D mixture in the following sequence; 0.1 ml of 2 
M sodium acetate (pH 4), 1 ml of water-saturated phenol, and 0.2 ml of chloroform- 
isoamyl alcohol mixture (49:1). The contents of the reaction tube were mixed by 
inversion after the addition of each reagent. The final suspension was shaken 
vigorously, cooled on ice for 15 min and centrifuged at 10,000 x g for 20 min at 
4°C. The RNA, present in the aqueous phase, was transferred to a second tube, 
mixed with 1 ml of isopropyl alcohol and placed at -20°C for 1 hour to precipitate
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the RNA. The RNA was pelleted by centrifugation at 10,000 x g for 20 min at 
4°C, dissolved in 0.3 ml of solution D and transferred to a clean 1.5 ml 
microcentrifuge tube. One volume of isopropyl alcohol was added and incubated for 
1 hour at -20°C. The RNA was pelleted by centrifugation, resuspended in 75% 
ethanol, sedimented a second time and the pellet was dried under a vacuum for 
approximately 15 min. The pellet was dissolved in 15 /*1 of sterile distilled water 
previously treated with diethyl pyrocarbonate (DEPC) (Sigma Chemical Co., St. 
Louis, Mo.) and stored at -40°C until needed.
The genomic region located in the carboxy terminus of the viral capsid VP3 
which had been previously reported as highly conserved in HAV (44) was selected 
as the target diagnostic sequence for PCR amplification and presumptive detection 
and identification of the virus. A second genomic region of 2.4 kilobases 
comprising the genes encoding capsid peptides VP1, VP2, and VP3 was also 
targeted for amplification from cDNA, generated after a reverse transcription 
reaction. The viral RNA was reverse-transcribed following the instructions of the 
manufacturer of the reverse transcriptase enzyme used (Boehringer Mannheim 
Biochemica, Indianapolis, IN). Two separate reactions in 50 pi volumes contained 5 
fi\ of 10X reverse transcriptase buffer (0.050 M Tris-HCl,(pH 8.3), 0.040 M KC1, 
0.006 M MgCl2), 5 ^1 of a 10X stock 0.1 M 1,4-dithioerythritol, 5 /j.1 of a 10X 
BSA stock (1 mg/ml), 2 mM of each deoxynucleotide triphosphate (dATP, dCTP, 
dGTP, dTTP), approximately 100 picomoles of the negative strand primer DC2 [5’- 
d(CTCC AG A ATCATCTCC)], for the VP3 carboxy terminus, or the OP2 [5’-
d(CCCAACTTCTAATCTCAG)] for the PI capsid encoding region, and DEPC- 
treated sterile distilled water. The mixture was heated to 95°C for 5 min and then 
incubated at 42°C for 10 minutes before addition of 20 Units of the Moloney 
Murine Leukemia Virus-Reverse Transcriptase (Boehringer Mannheim, Indianapolis, 
IN). The reaction was incubated at 42°C for one hour after which 2 /x 1 containing 
approximately 100 picomoles of the positive strand primer DC1 [5’- 
dACAGGTATACAAAGTCAG)] for the VP3 carboxy terminus, or RT1 [5’- 
d(GAGGTACTCAGGGGCATT)] for the capsid encoding region were added, 
followed by 5 ^1 containing 20 fxg of gelatin, and 5 Units of AmpliTaq DNA 
polymerase in a volume of 1/xl. The reaction mixture was overlayed with 100 /xl of 
mineral oil and subjected to 90 automated cycles in a DNA thermal cycler 480 
(Perkin Elmer Cetus, Norwalk, CT.). Following amplification, the DNA was 
ethanol precipitated by the addition of one tenth of the total reaction volume of a 2 
M sodium acetate solution and two volumes of 100% ethanol. The PCR products 
were resuspended in 15 of sterile distilled water and samples were 
electrophoresed in a 1% agarose gel and stained with a 0.5 fxg/ml ethidium bromide 
solution.
Antigen Capture Polymerase Chain Reaction Assay: Monoclonal 
antibodies with specificity for the Hepatitis A virus were tested in an immunoaffinity 
assay to assess their efficiency to capture Hepatitis A virus particles from a 
suspension. A modification of the method of Jansen et al. (44, 45) was used for this
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objective. Sterile 0.5 ml polypropylene microfuge tubes (Sarsted Inc., Princeton,
NJ, Perkin Elmer-Cetus, Norwalk, CT) were coated with 50 /xl of 0.05 M sodium 
carbonate buffer (pH 9.6) containing 10 /xg of antibody protein. The antibody- 
coated tubes were stored at 4°C until needed and incubated at 37°C for 4 hours 
before the blocking step. Following the incubation period, the coating buffer was 
carefully withdrawn with a micropipet and 60 /x 1 of PBS-1% BSA were added. The 
tubes were incubated for 1 hour at room temperature, and washed three times with 
100-200 n 1 of PBS - 0.05% Tween 20. Virus-containing samples, in a volume of 50 
/xl, were added to the anti-HAV coated tubes, incubated overnight at 4°C, and then 
washed with 100-200 /xl of a washing solution (0.020 M Tris-HCl,(pH 8.4), 0.075 
M KC1, 0.0025 M MgCl2).
The reverse transcriptase-Polymerase Chain Reaction was assessed in two 
formats. In both approaches, the highly conserved region of the HAV genome (44) 
located in the carboxy terminus of the capsid protein VP3 was selected as the target 
for amplification. The first approach followed a modification to the specified 
enzyme conditions from the manufacturer of the RT enzyme as mentioned previously 
in the Viral RNA Isolation section. The 50 /xl reverse transcription reaction 
contained 5 /xl of a 10X reverse transcriptase buffer (0.050 M Tris-HCl, (pH 8.3), 
0.040 M KC1, 0.006 M MgCl2), 5 /xl of a 10X 1,4-dithioerythritol (0.1 M), 5 /xl of 
a 10X BSA stock (1 mg/ml), 2 mM of each deoxynucleotide triphosphate (dATP, 
dCTP, dGTP, dTTP), 7 - 1 0  mM of the negative strand primer, DC2 [5’- 
d(CTCCAGAATCATCTCC)], and sterile distilled water to a volume of 47 /xl. The
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mixture was heated to 95 °C for 5 minutes to denature the virus and followed by 
incubation at 42°C for 10 minutes. Next, 2 /xl containing 40 Units of a ribonuclease 
inhibitor (Promega, Madison, Wi.) were added and then a MMLV reverse 
transcriptase (Boehringer Mannheim, Indianapolis, IN) was added in concentrations 
which ranged from 2 to 10 Units to give a final volume of 50 /xl. The reagents 
were mixed by a 3 second centrifugation pulse, and the tubes were incubated at 
42°C for 60 minutes. After incubation the tubes were heated to 99°C for 5 min to 
denature the reverse transcriptase enzyme followed by incubation at 5 °C for 5 
minutes.
The protocol described for the GENE AMP™ RNA PCR kit (Perkin Elmer 
Cetus, Norwalk, CT), for the amplification of the cDNA by Polymerase Chain 
Reaction was followed. The 50 /xl reverse transcriptase reaction was supplemented 
with 2 mM MgCl2, lOx PCR buffer II, 7-10 mM of the positive strand primer DC1 
[5’-d(ACAGGTATACAAAGTCAG), 2.5-5.0 Units of the AmpliTaq DNA 
Polymerase, and sterile distilled water to a final volume of 100 /x 1. The samples 
were overlayed with 100 /xl of mineral oil and subjected to 30 automated cycles of 
denaturation at 94°C for 1 min, annealing at 37°C for 2 min, and extension at 74°C 
for 3 min, with an additional cycle extension of 10 seconds after the sixth cycle.
The reaction products were ethanol precipitated and resuspended in 50 /xl of sterile 
distilled water.
In the second approach for the antigen capture RT-PCR, the protocol for the 
GENEAMP™ RNA PCR kit (Perkin Elmer Cetus, Norwalk, CT) was followed. In
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the reverse transcription protocol, a "master mixture" was prepared containing 5 
mM MgCl2, 10X PCR Buffer II, 1 mM concentrations of each deoxynucleotide 
triphosphate (dATP, dCTP, dGTP, dTTP), 7-10 mM of the negative strand primer 
DC2, and sterile distilled water. The reaction tubes were heated to 95°C for 5 min 
followed by the incubation at 42°C, after which 1 Unit of an RNase inhibitor, and
2.5 Units of the reverse transcriptase enzyme were added. The reaction was 
incubated at 42 °C for one hour after which the reaction tubes were heated to 99°C 
for 5 min to denature the reverse transcriptase enzyme followed by incubation at 
5°C for 5 minutes.
The PCR protocol followed the conditions already described in the first 
approach where the GENEAMP™ Kit was used. All PCR products were recovered 
by ethanol precipitation as described before and resolved by 1 % agarose gel and/or 
8% polyacrylamide gel electrophoresis followed by ethidium bromide staining.
RESULTS
Before monoclonal or polyclonal antibodies were assessed for their role in an 
immunoaffinity assay, the reverse transcription and amplification by polymerase 
chain reaction of two selected regions of the HAV genome were assessed. For this 
objective, the acid-guanidinium thiocyanate-phenol chloroform protocol of 
Chomczynski and Sachii (12) was used to isolate HAV genomic RNA. Quantitation 
of RNA was difficult due to extremely low recovery. From 5 x 109 virions, the
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quantity of RNA recovered was estimated to be approximately 2.8 picograms of 
genomic RNA, estimated by absorbance at 260 nanometers. Moloney-Murine 
Leukemia virus reverse transcriptase was chosen to generate the cDNA copy from 
viral genomic RNA.
For reverse transcription two sets of oligonucleotide primers were selected. 
The first set (OP2, RT1) were designed to amplify most of the PI region in the 
HAV genome. This region includes the genes which encode the viral capsid 
peptides VP1, VP2, and VP3, which includes approximately 2,369 nucleotides. The 
objective behind amplification of this genomic region was to utilize it as the cDNA 
template from which individual genes encoding the capsid peptides could be 
amplified. A second set of primers were designed for amplification of a region of 
191 nucleotides located in the carboxy terminus of the VP3 peptide (positive strand 
HAV +2020, negative strand -2211). This particular sequence had been reported 
by Jansen et al. (44) to be a conserved region in the Hepatitis A virus genome. 
During an epidemiological study these investigators examined and compared the 
genomic RNA sequences from HAV strains recovered from around the world. The 
epidemiological findings prompted Jansen et al. to suggest the mentioned sequence 
as a potential diagnostic sequence for presumptive detection and identification of the 
Hepatitis A virus.
The first attempt to amplify the 2.4 kilobases and the 191 nucleotide regions 
was unsuccessful. In a second attempt only the 191 nucleotide diagnostic region 
was successfully amplified after 90 automated cycles. The difficulty in amplification
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of the 2.4 Kb region could be explained as a consequence of two isolated or possibly 
combined factors. The first resides with the possibility that complex tertiary 
structures present in the RNA genome, impeded effective denaturation, primer 
annealing and reverse transcription of the PI genomic region. The second 
impediment may have resided with the fact that the protocol followed for reverse 
transcription and PCR did not take into consideration heat inactivation of reverse 
transcriptase enzyme prior to addition and start of the polymerase chain reaction.
The presence of the reverse transcriptase enzyme (RT) is known to interfere with the 
DNA polymerase which may cause the truncation or termination due to physical 
interference of the RT enzyme which competes for sites along the cDNA molecule. 
The destruction or denaturation of the reverse transcriptase activity relies on high 
temperature intervals achieved during automated cycles. Although the 191 
nucleotide region should possess a higher probability of being effectively copied into 
cDNA and amplified when compared to a 2.4 kilobase fragment, the signal obtained 
following 90 automated cycles was very low. In addition to difficulties encountered 
with the reverse transcription event and/or cDNA amplification, the sensitivity of the 
complete assay was low. The amplification signal generated from 5 x 109 virions 
was unacceptable if the current method was used for RNA purification followed by 
RT-PCR to detect HAV. However, this was not the objective of this investigation 
but rather to evaluate the feasibility of reverse transcribing and amplifying selected 
portions of the HAV genome.
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Figure 3 outlines the capture RT-PCR approach to be followed for detection 
of Hepatitis A virus. To assess the antigen capture-RT-PCR, a battery of anti-HAV 
monoclonal antibodies were tested at 10 micrograms of MAb protein per reaction 
tube. Each tube was coated with the monoclonal antibody protein in carbonate 
buffer at pH 9.6. Initial assessment of the immunoaffinity-RT-PCR detection assay 
was done by using 2 x 106 viral particles and then utilizing the PERKIN-ELMER 
GENE Amp PCR kit. The six monoclonal antibodies tested were P1-C4, P2-G11, 
P l-E ll , P4-B8, P6-B5, and P2-G9 . Following successive attempts to amplify the 
191 nucleotide diagnostic region, subsequent assays were confined to MAb P2-G9 
and P l-E ll in order to save reagents. Again, amplification was unsuccessful. A 
modification was introduced into the RT-PCR protocol, by applying reaction 
conditions for the reverse transcriptase reaction specified by a different RT-enzyme 
manufacturer, Boehringer Mannheim. The protocol steps which followed the 
reverse transcription reaction were the specifications of the PERKIN-ELMER kit.
The rationale was that the positive control, included in previous reactions where 
amplification was attempted from VP3 cDNA, which contained the target genomic 
region, always showed effective amplification of the 191 nucleotide fragment. This 
finding ruled out difficulties associated with conditions for the amplification reaction 
and narrowed the potential obstacle to the reverse transcription reaction and/or the 
efficiency of capture of HAV. Successful amplification of the 191 nucleotide 
sequence was obtained at 5 x 108 virions per 50 fx.1 sample, or 1010 virions/ml. 
However, no amplification was obtained at lower dilutions tested (106, IQ4, 102
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virions per 50 pel). In this experiment, the automated cycles were extended to 60 
cycles, and amplification was obtained only with the capture MAb P2-G9. Figure 4 
shows the amplification products obtained. The sequence amplified corresponded to 
the target 191 nucleotide product (shown in lane 1). The negative control consisted 
of an antibody coated tube to which no virus was added before RT-PCR. As 
expected, no signs of amplification could be detected. The positive control consisted 
of a reaction to which no virus was added, but 32 nanograms of VP3 cDNA were 
added prior to PCR amplification. The amplified signal or resolved band 
demonstrated efficient amplification of the target sequence. The results suggest that 
difficulties observed when low concentrations of HAV were tested was not due to 
PCR amplification but to difficulties in steps preceding PCR amplification.
To examine and compare additional experimental conditions for the reverse 
transcriptase reaction, the method of Jansen et al.(44, 45) was tested in the reverse 
transcription reaction. No amplification was obtained at any virion dilution 
following 60 automated cycles when MAb P2-G9 was used in the capture step. The 
reverse transcriptase enzyme used was the MMLV enzyme supplied in the PERKIN- 
ELMER kit. The concentration of enzyme was tested from 2.5 to 10 units. Next, 
the RT reaction conditions specified by Boehringer Mannheim were assessed using 
the reverse transcriptase enzyme from the PERKIN-ELMER kit. After testing the 
same virus dilutions no amplification was obtained.
The possibility that RNase activity seemed a viable explanation for the failure 
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Figure 3: Outlined sequence of events in the immunoaffinity assay coupled to 
reverse transcription and amplification of a target region of the HAV 
genome by polymerase chain reaction The antigen capture step used 
monoclonal or polyclonal antibodies with specificity for HAV (1).
Release of the viral genome was attained by heating to 95 °C for 5 
minutes (2). The target sequence for reverse transcription was located in 
the carboxy terminus of the viral capsid peptide VP3 (3). After reverse 
transcription the target sequence cDNA was amplified by polymerase 
chain reaction (4).
Figure 4: Ethidium bromide stained 8% polyacrylamide gel of amplified products 
after 60 automated cycles. Amplification reaction for sample containing 
1010 PFU/ml (Lane 1). Negative control reaction where no virus was 
added to reaction tube before RT-PCR (Lane 2). Positive control reaction 
(Lane 3). BioMarker-Low molecular weight marker (Lane 4).
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low antibody affinity for the specific epitope, could also account for the failure to 
generate an amplification signal.
Another possible explanation for the lack of sensitivity in the AC-PCR assay 
was the fact that the virus used for the assays had been inactivated by treatment with 
formalin at a 1:1000 dilution (M. D. Sobsey, personal communication). Although 
guanidinium thiocyanate is considered an effective protein denaturant (12), it is 
difficult to predict the effect that formalin-fixed capsomeres may exert in the release 
of the viral genome due to RNA-protein cross-linking. This possibility will exert a 
direct effect in the reverse transcription reaction. Formalin fixation is certainly a 
more serious problem for the immunoaffinity assay since no protein denaturants are 
present in the reaction components and the denaturation of the capsid is attained 
solely by heat denaturation at 95°C for 5 minutes.
To confirm or acquire more insight in the validity of the later explanation an 
ELISA was developed using fractionated rabbit immunoglobulins against the intact 
Hepatitis A virus as capture antibody. The rationale for this experiment was to 
assay several dilutions of the virus before and after boiling at 95°C for 5 minutes, 
followed by incubation at 42 °C for 10 minutes as performed in the RT-PCR assay.
If the boiling step destroyed the viral capsid, this would be reflected by a decrease 
in absorbance, since the secondary antibody, a mouse anti-HAV will not bind to the 
denatured capsid. The results showed no significant decrease in the Absorbance 
readings after the virions were subjected to the heating steps, which suggested 
preservation of the intact protein capsid fixed by the formalin treatment.
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Impairment of the release of the viral genomic RNA from formalin-fixed HAV may 
account for low sensitivity observed.
DISCUSSION
Since its introduction, the polymerase chain reaction has increasingly found 
applications in monitoring a wider range of microorganisms from the environment. 
Among these applications, the technique has been considered in the monitoring of 
safety standards of water supplies on the basis of detection of coliform bacteria and 
Escherichia coli as a specific indicator of human fecal pollution (4). However, as 
discussed in the introduction, the bacteriological monitoring of water supplies does 
not reflect the presence of enteric viral pathogens and there is a need for the 
regulation and monitoring of pathogens of this nature. PCR is a technique that 
provides an exquisite sensitivity for the detection and monitoring of these pathogens. 
Jansen et al. (44, 45) combined the technique with the specificity of an antigen- 
antibody reaction to capture the Hepatitis A virus demonstrating the potential for the 
technique as a detection and monitoring assay.
In the present research, we set to develop the serological components for an 
antigen capture-PCR assay intended for future assessment in the detection of HAV 
from seafood samples. The hybridoma P2-G9 demonstrated neutralization activity 
and proved satisfactory for capturing the virus when tested in the AC-PCR assay. A 
problem that needs to be addressed is the improvement of the sensitivity of the assay
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since the amplification obtained reflected a sensitivity inferior to established 
techniques such as gene probe. Two obstacles confronted in this study were the 
limited availability of viral material for immunizations and assay development which 
was compounded by the dependency on a formalin-fixed virus for all experimental 
manipulations. This limitation resided in the inability of generating the virus in our 
own tissue culture facilities due to the containment requirements for growth and 
manipulation of this viral pathogen. The formalin fixation is presumed to have 
influenced the effective denaturation of the viral capsid during the heating step 
before the reverse transcription reaction and possibly the native state of the viral 
RNA. It is known that formaldehyde combines with uncharged amino groups to 
form weakly basic derivatives. Walker (88) discussed the effects of formaldehyde 
inactivation on the production of the poliomyelitis vaccine. The process of 
formaldehyde inactivation is described as an initial surface interaction of the 
formaldehyde with the capsid peptides after which the formaldehyde will gradually 
diffuse through the virus. Although not discussed by Walker the possibility of 
formaldehyde reacting with available amino groups in the interior of the viral capsid 
protein and also with groups present in the nucleic acid material could explain the 
inability to disrupt the capsid and/or reverse transcribe the HAV genome.
Another consideration is the fact that the viral capsid is well known to be 
destroyed by boiling in water for 1 minute (9). However, the HAV capsid is also 
known for its resistance to temperature extremes such as heating at 65°C for 2 min. 
and 78°C in the presence of molar MgCl2 (75). This reagent is present in the buffer
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systems in the RT-PCR reaction although at a low concentration. At this point is 
only speculative if formalin fixation would have any synergistic effect once in the 
presence of MgCl2, accounting for resistance to the 95 °C treatment for the five 
minute period. The reason for narrowing the source of the problem to the 
denaturation of the viral capsid is based on numerous conditions assessed in the 
development of the assay. The intact nature of the viral nucleic acid was 
demonstrated when the viral RNA was used as a template for amplification after 
isolation by the method of Chomczynski and Sachii (12). In this method, 
guanidinium thiocyanate, a strong protein denaturant, was used to separate and 
isolate the nucleic acid material from the capsid shell. The isolated RNA served as 
a template for the successful amplification of the target nucleotide sequence of 191 
nucleotides demonstrating the intact nature of the target sequence. However, as 
mentioned before, the amplification signal obtained was also low after 90 automated 
cycles.
In a different sets of experiments the aliquot containing the HA virions was 
included in the reverse transcriptase reaction volume to assure the presence of the 
virus throughout the following steps of denaturation and reverse transcription, and 
ruling out the possibility of lack of retention or capture of the virus by the antibodies 
coating the reaction tube. Again, the failure to obtain amplification of the nucleic 
acid suggested difficulties with the release of the viral RNA. Taking into 
consideration the experimental approaches discussed before, it will be necessary to 
assess the RT-PCR assay using a non-fixed, viable virus. This conditions will help
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to define the necessary adjustments for the improvement of the sensitivity of the 
assay under conditions where the viral RNA is not altered and/or inaccessible for 
amplification.
Another point that deserves consideration is the limited availability of viral 
material for use as immunogen during the immunization protocols. As previously 
discussed, the immunization doses have been reported as sub-optimal by previous 
studies (40, 54). This factor, undoubtedly accounts for the low neutralizing activity 
since affinity maturation of the anti-HAV antibodies could not be accomplished if an 
immune response was being elicited with sub-optimal doses of capsid protein. To 
circumvent the problem, an immunization regime based on the use of adjuvant 
emulsions was assessed with interesting results. All the clones generated with the 
exception of P l-E ll were of the IgM immunoglobulin class, supporting the previous 
interpretation where each of the adjuvant injections served as a primary 
immunization instead of promoting and prolonging the secondary immune response 
after the initial immunization with the complete adjuvant.
A few other points need to be taken into consideration besides the particular 
limitations found in this part of the study. The first relates to the transfer of a 
technique of the nature of antigen-capture-reverse transcriptase-polymerase chain 
reaction (AC-RT-PCR) from the research laboratory to the field laboratory for 
routinary use as a detection/diagnostic assay. Although the technique offers a 
protocol for an unsurpassed sensitivity, it is not free of complications. One crucial 
difficulty faced by an assay of the nature of AC-RT-PCR is the sample or specimen
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cleaning to an extent where it is compatible with the assay to be performed. Sample 
clean-up has been assessed with several recommendations depending on the nature of 
the specimen. Manipulations such as polyethylene glycol precipitation, spin column 
chromatography, and ultrafiltration are among several alternatives assessed. All 
intended to eliminate agents that may interfere with the nucleic acid amplification.
Besides the technical difficulties inherent to the assay, there are other 
parameters that need to be defined in relation to the specific pathogen, being the 
Hepatitis A virus in this particular study. For this specific enterovirus, there is a 
lack of information regarding its persistence in the environment. Since shellfish, 
specifically oysters, are known to feed by filtration of the surrounding water, they 
constitute a source for concentration of the viral pathogen and consequently a 
potential concentrated inoculum for the pathogen upon ingestion. There is a need to 
define the infectious dose for the virus and its survival after treatment of the oyster- 
surrounding waters if depuration and cleansing of the oysters is considered for the 
elimination or reduction of the bacterial and viral burden in the oyster. All these 
factors need to be kept in mind when assessing a technique with a capability of 
detection as low as one to five genome copies of the target sequence (4, 18). If no 
infectious dose has been defined, such a high sensitivity would not have a valuable 
or applicable meaning. It is also necessary to consider the nature of the genomic 
material targeted for amplification since the possibility of efficiently amplifying a 
specific sequence from a non-living organism is always present. RNA is not as 
persistent as DNA and is known to rapidly degrade upon water treatments such as
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chlorination as reflected by a corresponding decrease in the capability to amplify a 
target sequence after RT-PCR (18). This observation helps to ensure the correlation 
between an amplified signal and the presence of the HAV without having to consider 
the cultivation of the pathogen to back the observed results or the risk of 
amplification of residual nucleic acid material when the pathogen is not present.
Most important of all is the fact that no mandatory inspection for seafood 
operations has been defined by the Federal government. Currently only the beef and 
poultry industries have been subjected to mandatory inspection. It is imperative for 
the seafood industry specifically for shellfish operations, that regulations be outlined 
in reference to cultivation, handling, processing, and monitoring of potential 
pathogens of bacterial and/or viral nature. Once this step is taken it will be 
followed by the assessment of methods and techniques available with the purpose of 
attaining and monitoring the imposed regulations. The transferability of such 
technologies and the feasibility for the routinary laboratory environment, and their 
cost effectiveness will all be factors to consider by the regulatory agency.
CHAPTER HI





Current infection by the Hepatitis A virus is confirmed clinically by detection 
of anti-HAV specific antibodies of the IgM subclass in the blood serum of the 
subject. Anti-HAV antibody is the first serological marker presenting itself with the 
characteristic abrupt onset of symptoms. An acute titer of anti-HAV IgM appears 
early in the course of illness, reaching a maximum at one to two weeks following 
onset of symptoms. Anti-HAV IgM antibody can be detected for a period which 
ranges from 3 to 6 months post infection. The presence of the IgM response 
permits diagnosis of an acute or recent HAV infection (17, 21). Following the 
course of an immune response, the IgM titer will decrease while an anti-HAV IgG 
titer will appear and persist for years following recovery from HAV infection. The 
anti-HAV IgG response confers permanent immunity against future exposure and 
gives evidence of past exposure to HAV, from serological criteria. The role of 
secretory immunity during Hepatitis A infection has been assessed (65, 94), 
however, IgA does not seem to play a significant role in protection against this HAV 
infection, contrasted with the relevant role IgA plays against other Enteroviral 
infections (81).
Several serological approaches have been developed to detect antibody to 
Hepatitis A virus in blood serum, such as, immunoelectron microscopy (25, 26), 
complement fixation (72), radioimmunoassay (8), and enzyme immunoassays (21,
24, 52, 74, 89). These methods have been applied to both detect HAV particles or
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anti-HAV antibody. Commercial immunoassay kits have been developed which 
detect total antibody to HAV and IgM acute antibody only (17, 78). The assay 
currently employed in most clinical laboratories is a fully automated microparticle 
enzyme immunoassay, IMxHAVAB, developed by Abbot Laboratories (Abbot Park, 
Chicago, IL.). The IMxHAVAB assay is designed for detection of total serum 
antibody (IgM and IgG subclasses) against the Hepatitis A virus in an automated 
Abbot instrument (74). In this assay microparticles coated with tissue-culture grown 
Hepatitis A virions are incubated with the serum specimen. The mixture is 
transferred to a glass fiber matrix where separation of bound from unbound material 
takes place. If anti-HAV is present in the serum specimen it will bind to the HAV- 
coated microparticles and is retained by the glass fiber matrix. At this stage an anti- 
HAV:alkaline phosphatase conjugated antibody is added, followed by substrate, and 
a fluorescent signal generated by the dephosphorylation event is registered. The 
fluorescence rate increase is inversely related to the amount of anti-HAV captured 
by the HAV coated microparticles.
The use of tissue culture grown HAV involves containment facilities for 
cultivation of this viral pathogen. The operation of such a costly facility is also 
confronted by common complications associated with the growth of viruses in cell 
lines such as variations in the infectivity properties of virus isolates. This is further 
complicated by the difficulties associated with cultivation of Hepatitis A virus which 
is known to grow poorly and slowly in tissue culture (13, 89, 92), sometimes 
resulting in cell-line infections which produce no discernible cytopathic effect (16,
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50). The possibility of substituting subunits of the viral capsid or synthetically 
synthesized capsid peptides which contain the relevant epitopes of the Enteroviral 
capsid for tissue culture generated virions would be considered a time-saving and 
inexpensive alternative to using whole virions. Such an effort requires 
characterization of the immunodominant sites in the viral capsid of the Hepatitis A 
virion.
Several investigators have identified the dominant neutralization epitopes in 
the capsid of the Hepatitis A virus with the goal for construction of synthetic 
peptides for vaccine development (3, 22, 23, 31, 39, 40, 82). Hughes et al. (40) 
and McGregor et al. (54) produced monoclonal antibodies against the Hepatitis A 
virus as the first step in the development of research and/or diagnostic reagents. 
Hughes et al. (40) attempted to locate the major neutralization site(s) in the HAV 
capsid by use of monoclonal antibody. They demonstrated the existence of a major 
neutralization site in the viral capsid peptide VP1, however, each of the four 
monoclonal clones they used did not react, serologically with disrupted capsid 
proteins by either immune precipitation or Western blot analysis, which suggested 
the existence of a conformational epitope. Stapleton, and Lemon (82) confirmed the 
findings of Hughes et al. (40). They detected a single dominant neutralization site 
with monoclonal antibodies through identification of neutralization escape mutants. 
However, in a later publication, Ping et al. (67) reported that VP3 may contribute to 
the major neutralization epitope, which supported the findings of Hughes et al. (39) 
from which they reported neutralization and precipitation of intact HAV virions by
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antibodies specific for viral peptides VP1 and VP3. Although neutralization and 
precipitation activity for anti-VP2-specific antibodies was poor, compared to VP1 or 
VP3, the authors suggested that each structural peptide (VP1, VP2, and VP3) 
contain or contribute to the neutralization epitope (39).
The serological approach used to characterize the immunodominant sites in 
the capsid proteins of the Hepatitis A virion was significantly accelerated by 
application of molecular biology techniques. The genome of the Hepatitis A virus 
was shown by Coulepis et al. (15) to be a single stranded RNA molecule, and the 
picornaviral genome has been characterized by several investigators (2, 3, 13, 86). 
Ticehurst et al. (86) reported cloning cDNA which represented greater than 99% of 
the genome of the Hepatitis A virus. Subsequent analysis of the viral genome 
progressed to the full characterization of the viral genomic RNA sequence, which 
identified the protein products encoded by HAV (2, 3, 13, 39, 55, 75, 76). The 
systematic elucidation and sequencing of genomic regions encoding for the viral 
capsid immunodominant epitopes lead to the consideration of molecular approaches 
for development of synthetic vaccines. The potential for the development of an 
HAV vaccine was also supported by accomplishments in the development of 
vaccines for the Foot and Mouth disease virus and for the human Poliovirus, both 
also members of the Picornaviridae family of viruses.
Although the initial approach used in the development of an HAV vaccine did 
not involve molecular biology techniques, Provost ana Hillerman (70) were the first 
to demonstrate effective protection following immunization of marmosets with
formalin-inactivated HAV harvested from a crude infected marmoset liver extract. 
Although the formalin-HAV demonstrated potential for development of a protective 
vaccine, the crude extract utilized was not suitable for large scale utilization in a 
commercial setting. These findings launched an effort to adapt the Hepatitis A virus 
to cell culture with the goal of generating a suitable and clean vaccine for use in 
humans (29, 30, 51). Currently, a killed HAV vaccine is in clinical trials (27, 91), 
yet, it is recognized that a vaccine produced by inactivation and fixation of virion 
particles, is likely to provide only temporal protection, and may require 
administration of multiple vaccine doses and as a consequence production of large 
amounts of the virus. Working on this premise, investigators at the Merk Institute 
and at the National Institutes of Health (NIH) embarked in a program to develop a 
live vaccine consisting of attenuated variants of HAV. Ross et al. (75) reported that 
a combined Merck-NIH effort showed that production of a live attenuated vaccine 
was feasible. However, they cautioned there was a need to determine the role of 
secretory immunity following active immunization with the Hepatitis A virus and 
determine the potential for HAV reversion to a virulent state. This last concern 
emphasized the need to characterize completely the molecular changes leading to 
viral attenuation rather than attempting to reach this objective by serial passage of 
HAV in tissue culture.
Cohen et al. (13, 14) produced a cDNA copy of the Hepatitis A virus with 
the goal of constructing a recombinant virus which contained genomic regions of 
attenuated and wild type viruses. This approach was designed to determine the
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sequences responsible for attenuation obtained following serial passage in tissue 
culture.
Alternate approaches used in vaccine development take advantage of modem 
techniques directed to production of subunit vaccines. The advantage of the subunit 
vaccine approach are, the economy in the production of synthetic products, quality 
control of synthetic products is not subject to the mutational risks which accompany 
viruses grown in tissue culture, and finally the safety of the non-viable subunit 
product when compared to attenuated or killed vaccines. This approach to vaccine 
development requires a profound knowledge of the molecular structure of the 
pathogen namely the protective immunodominant epitopes which provoke 
neutralizing antibody. Sequence analysis of the Hepatitis A virus genome and 
molecular cloning of these sequences which encode structural capsid proteins 
provided a means by which individual oligopeptides can be produced synthetically or 
expressed in prokaryotic or eukaryotic systems.
Baroudy et al. (3) elucidated the sequence from the 3’ and 5’ terminal 
regions of the HAV genome prepared from a complementary cDNA copy of the 
RNA genome. In their study they discussed the potential for production of synthetic 
peptides and also the potential for cloning HAV sequences in prokaryotic or 
eukaryotic expression systems. Hughes et al. (39) assessed the immunogenicity of 
isolated structural proteins by immunizing rats with various doses of individual viral 
peptides (10 - 15 fig per dose). They reported production of neutralizing antibodies 
in rats immunized with the VP1 and VP3 peptides and to a lesser degree against the
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VP2 peptide. The serological findings suggested the three major peptide 
components of the viral capsid participate or contribute to form a conformational 
antigen, which influence neutralization of the virus by antibody.
Emini et al. (23) compared the amino acid sequences of the VP1 capsid 
peptides of Poliovirus type 1 and Hepatitis A virus. Their study predicted 
similarities in the secondary structure of the VP1 capsid peptides and identified 
probable antigenic sites which served in antibody neutralization. A VP1 synthetic 
peptide reacted with antibodies in hyperimmune serum raised against intact HAV, 
which suggested the peptide possessed conformation equivalent to that of the intact 
virion capsid. Experimental animals immunized with the synthetic peptide 
produced anti-peptide antibodies which possessed affinity for the intact Hepatitis A 
virions and were also capable of neutralizing the infectivity of HAV in cell culture.
In addition to reacting with the intact virion, the anti-peptide antibodies also reacted 
with purified denatured HAV VP1 which suggested the epitope may be a linear 
determinant. They concluded that recognition of either the intact virion capsids or 
the denatured capsid peptide by anti-peptide antibodies suggested the selected peptide 
sequence possessed potential as a component in a synthetic HAV vaccine.
Several research groups pursued cloning and expression of viral products in 
Escherichia coli. Ostermayr et al. (64), and Gauss-Muller et al. (31) independently 
designed prokaryotic expression systems for synthesis of fusion proteins of Beta- 
galactosidase and HAV capsid peptides. The first group (64), reverse transcribed 
the entire HAV genome and proceeded to clone cDNA regions which encode for a
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portion of the viral capsid protein VP1 into an expression vector, and produced a /3- 
galactosidase fusion peptide. Rabbit serum generated against intact virions reacted 
with the recombinant proteins, however, human convalescent serum did not react 
serologically with the VP1 fusion peptide when examined by Western Blot. In a 
second approach, Gauss-Muller et al. (31) selected six overlapping genomic regions 
of the capsid proteins VP1 and VP3 for cloning and expression of fusion peptides. 
From the various cloned regions, they identified two recombinant proteins that 
induced neutralizing antibody production in rabbits only after the animals received a 
primary challenge with suboptimal doses of the Hepatitis A virus. Although they 
did not assess the serological reactivity of the fusion peptides with human immune 
serum, a finding common to both studies was that immune rabbit sera does 
recognize the fusion peptides. One obstacle, reported by both groups, was the poor 
solubility exhibited by the fusion peptides, a difficulty which hindered their efforts 
to develop immunoassays for detection of anti-HAV antibodies.
Alternate approaches for vaccine development include, the expression of 
HAV polyprotein in recombinant baculoviruses (83), and in Vaccinia virus (92).
The Vaccinia model proved more advantageous since the expressed polyprotein was 
processed into capsid structures that migrated with empty HAV capsids in sucrose 
gradients (92), whereas the baculovirus system did not assemble the virion capsid 
(83, 92). Harmon et al. (36) reported cloning the cDNA genomic region encoding 
HAV capsid protein VP1 and the flanking portions of VP3 and the P2 region into 
the genome of the Auto graph a californica nuclear polyhedrosis virus and subsequent
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expression in an insect cell culture line. The cell lines produced high levels of a 55 
kDa protein which contained the VP1 peptide, confirmed by immunoblot assay 
which used human anti-HAV convalescent serum and rabbit immune serum obtained 
from animals immunized with intact HAV. They recovered the HAV protein 
exclusively from the pellet fraction in their preparations, suggestive of low solubility 
for the peptide.
HAV vaccine testing which employs recombinant peptides reported variable 
results in producing a neutralizing immune response. The consensus is that the 
capsid peptide VP1 possesses the primary conformational epitope against which the 
immune response is directed. However, the contribution of the VP2 and VP3 
peptides to the conformation of the capsid epitope remains unresolved. In summary, 
research to date points to the need for a better understanding of the role and the 
applications of such peptides as immunogens intended for confering of long life 
immune protection.
The objective of this investigation is to assess the application of molecularly 
cloned capsid peptides from the Hepatitis A virus in the development of an 
immunoassay. The production of individual viral capsid peptides was attempted in a 
prokaryotic expression system as fusion peptides to the j8-galactosidase enzyme.
The immunogenic identity of the molecularly generated peptides was assessed with 
serum generated against intact Hepatitis A virions.
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MATERIALS AND METHODS
Bacterial Strains and Plasmids: Bacterial strains and expression plasmids 
were kindly provided by Dr. John R. Battista, Louisiana State University, Baton 
Rouge, and are listed in Table 2.
Viral cDNA Amplification: The plasmid pGEM-HAV (12), provided by 
Dr. Robert H. Purcell, NIH, was used to amplify the 5’ capsid encoding region of 
the Hepatitis A virus. A 2.4 Kb DNA fragment containing the viral genomic 
regions encoding for the viral capsid peptides VP1, VP2, and VP3 was selectively 
amplified using the Polymerase Chain Reaction (Perkin Elmer-Cetus, Norwalk,CT). 
A 100 (x\ reaction mixture containing lOx reaction buffer (100 mM Tris-HCl, pH 
8.3, 500 mM KC1, 15 mM MgCl2, 0.01% (w/v) gelatin), 220ng/22ng/2.2ng/0.22ng 
of pGEM-HAV DNA, 200 /xM of each dNTP, 0.100 /xM of the positive strand 
primer RT1 [5’-d(GAGGTACTCAGGGGCATT)], 0.100 of the negative strand 
primer OP2 [5’-d(CCCAACTTCTAATCTCAG)] and 5 Units of AmpliTaq DNA 
Polymerase were overlayed with 100 (x\ of mineral oil and subjected to 30 automated 
cycles of denaturation at 94°C for lmin, annealing at 37°C for 2min, and extension 
at 74°C for 3min, with an additional cycle extension of 10 sec after the sixth cycle. 
The reaction products were ethanol precipitated and resuspended in 50 y.\ of sterile 
distilled water.
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TABLE 2: Bacterial strains and plasmid vectors
Strains/Plasmids Description Reference
Escherichia coli GW1000 xyl-5, mtl-1, galK2, X-raC, rpsL3\, G. Walker/
kdgk5\, A(gpt-proA)62, focYl, tsx-33, J. R.Battista
5W/7E44, r/i/-1, /ewB6, hisG4, mgl-51, (L.S.U.)
arg-3, rfbDl, ara-14, r/zr-l, recA441, 
sw/A, ivt, A/tfcU169, p ra +
Escherichia coli CSR603 recAl, wvrAl, phrl, thrl, leuB6,
argE3, thi 1, aral4, tocYl, ga/K2, 





pAX4b + United States 
Biochemical
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Two approaches were considered for the amplification and cloning of the 
individual viral capsid cDNA sequences from the 2.4 Kb fragment amplified 
previously. In the first approach, specific oligonucleotide primers were designed for 
the selective amplification of the regions corresponding to the viral capsid sequences 
for VP1, VP2, and VP3. The primer sequences corresponded to the extreme ends 
internal to the viral capsid sequences therefore, generating amplified blunt-ended 
PCR products. For the amplification of the genomic region encoding for the viral 
capsid peptide VP1, the negative strand primer VP-l-NS [5’ - 
d(TCTCAAATCTTTTATCTTC)] and the positive strand primer VP-l-PS [5’ - 
d(GTTGGAGATGATTCTGGA)] were designed. Amplification of the VP2 region 
was accomplished with the negative strand primer VP-2-NS [5’ - 
d(TTTGTGTAGAAAGAGGAGT)] and the positive strand primer VP-2-PS [5’ - 
d(GACATTGAGGAAGAGCAA)]. For amplification of the VP3 region, the 
negative strand primer VP-3-NS [5’ -d(TTTGTGTAGTAACATCCAT)] and the 
positive strand primer VP-3-PS [5’ -d(ATGAGAAATGAATTTAGG)] were 
designed. The PCR amplifications were performed following the Perkin-Elmer 
protocol. A 100 /x 1 reaction mixture containing a 10X reaction buffer (100 mM 
Tris-HCl, pH 8.3, 500 mM KC1, 15 mM MgCl2, 0.01% (w/v) gelatin), 200 /xM of 
each dNTP, 20 /xM of each oligonucleotide primer, 500 ng of the previously 
amplified 2.4 Kb cDNA fragment, and 5 Units of the Taq DNA polymerase was 
used. The amplification reaction was extended to 45 automated cycles. After 
amplification, the DNA was precipitated by addition of 2M sodium acetate and two
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volumes of 100% ethanol. The PCR fragments were resuspended in 50 fi\ of sterile 
distilled water, the DNA concentration was determined by absorbance at a 
wavelength of 260 nanometers.
In the second approach, the oligonucleotide primers were designed containing 
flanking restriction enzyme sequences with the objective of facilitating the forced 
and directional cloning of the amplified viral genomic fragments. For the 
amplification of the genomic region encoding for the viral capsid peptide VP1, the 
negative strand primer NS-l-Hind [5’-
d(CCAAGCTTCCCTCAAATCTTTTATCTTC)] and the positive strand primer PS- 
1 -Eco [5’-d(CCGAATTCTGTTGGAGATGATTCTGGA)] were used. Amplification 
of the genomic region encoding for the viral capsid peptide VP2 was accomplished 
by use of the negative strand primer NS-2-Hind [5’-
d(CCAAGCTTTGTGTAGAAAGAGGAGT)] and the positive strand primer PS-2- 
Eco [5’-d(CCGAATTCTATGGACATTGAGGAAGAG)] were used, For the 
amplification of the genomic region encoding for the viral capsid peptide VP3 the 
negative strand primer NS-3-Eaw [5’-
d(CCAGGATCCCCTTGTGTAGTAACATCCAT)] and the positive strand primer 
PS-3-Ea? [5’-d(CCGAATTCTATGAGAAATGAATTTAGG)] were used. The PCR 
amplifications were performed following the Perkin-Elmer protocol. A 100 /d 
reaction mixture containing 10X reaction buffer, 200 /nM of each dNTP, 1.0 /nM of 
each oligonucleotide primer, 500 ng of the previously amplified 2.4 Kb fragment 
DNA, and 5 Units of the Taq DNA polymerase were mixed as indicated in the
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Perkin-Elmer protocol. The amplification was extended to 45 automated cycles.
After amplification, the DNA was ethanol precipitated and resuspended in 50 fA of 
sterile distilled water.
The DNA concentration of the amplified VP products was determined by 
absorbance at 260 nanometers. Approximately seven micrograms of amplified VP 
DNA were subjected to restriction enzyme digestion to generate the cohesive ends 
necessary for the ligation to the plasmid vector. A 100 fil restriction enzyme 
reaction for the VP1 and VP2 DNA contained 20 Units of the £coRI restriction 
enzyme (GIBCO BRL, Gaithersburg, MD). The digestion reaction was incubated 
for approximately 9 hours to assure complete digestion of the DNA. After 
incubation, the enzyme was inactivated by heating to 65°C for 10 minutes and the 
VP DNA was recovered using a Geneclean II Kit (Bio 101 Inc., LaJolla, CA). The 
recovered DNA was resuspended in 30 fxl of sterile distilled water and subjected to 
the second restriction enzyme digestion. A 100 reaction containing 20 Units of a 
Hind III restriction endonuclease (GIBCO BRL, Gaithersburg, MD) was incubated 
for approximately 9 hours. After the incubation period, the VP DNA was recovered 
using the Geneclean II Kit. The DNA was resuspended in 15 to 20 fxl of water and 
the DNA concentration measured by A260. The digested VP DNA was stored at - 
40°C until needed.
The restriction enzyme reaction for the VP3 DNA fragment was performed 
in a 100 fx 1 reaction volume. Approximately 7 /xg of amplified VP3 DNA were 
digested simultaneously with 30 Units of the EcoRI and 30 Units of the ZtawHI
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enzymes since the reaction buffer for both enzymes was compatible. The restriction 
enzyme reaction was incubated at 37°C overnight (9-12 hours). After incubation the 
DNA was recovered using the Geneclean II Kit and the resuspended in 20 (xl of 
sterile distilled water.
Cloning of Digested PCR Viral Capsid DNA: The expression plasmids 
pTTQ18 (Amersham Corporation, Arlington Heights, 111.), and pAX4b+ (United 
States Biochemical Corp., Cleveland, OH), were selected for the cloning of the 
amplified PCR products. This first expression vector contains a polylinker/lacZ 
alpha region downstream of a trp-lac (tac) promoter. The second, contains the 
entire lacZ encoding region downstream of a lac promoter, generating a translational 
fusion peptide containing the entire /3-galactosidase molecule. Both plasmids were 
amplified in an Escherichia coli GW1000 host strain in the presence of Ampicillin 
(lOOug/ml). Plasmid DNA was purified by a modification of the alkaline lysis 
method (6, 43).
For ligation of the blunt-ended amplified VP fragments the vector DNA was 
digested with the restriction endonucleases EcoRI and Hindlll. The staggered ends 
left by the restriction enzyme digestion of the plasmid were eliminated by digestion 
with a Mung-Bean nuclease enzyme (GIBCO BRL, Gaithersburg, MD). A 20 (xl 
reaction containing a 10X reaction buffer (300 mM sodium acetate, pH 4.5, 500 
mM NaCl, 10 mM ZnCl2, 50% (w/v) glycerol), plasmid DNA previously digested 
with restriction endonucleases, sterile distilled water, and 5.5 or 11.0 Units of the
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Mung-Bean nuclease enzyme were incubated at 37°C for one hour. After nuclease 
digestion the plasmid DNA was purified by phenol-chloroform extraction and 
recovered by ethanol precipitation.
To avoid the re-annealing of the plasmid DNA, the terminal phosphate 
groups of the previously generated blunt ends were removed by use of a calf 
intestine alkaline phosphatase enzyme (CIAP) (Stratagene, La Jolla, CA). A 20 /xl 
volume reaction containing 2.55 Units of the CIAP enzyme, a 10X CIAP buffer 
(500 mM Tris-HCl, pH 8.0, 1 mM EDTA), sterile distilled water, and plasmid 
DNA were digested for 30 minutes at 37°C. After incubation, the phosphatase 
reaction was stopped by addition of 4.1 /xl of a 250 mM EDTA followed by 
incubation at 68°C for 15 minutes. Plasmid DNA was extracted two times with 
phenol-chloroform and the DNA was precipitated with two volumes of ethanol.
Before ligation the PCR amplified products were subjected to phosphorylation 
at the 5’ ends by use of a T4 polynucleotide kinase enzyme (GIBCO BRL, 
Gaithersburg, MD). The kinase reactions for the PCR fragments contained 20 Units 
of the T4 kinase enzyme in a 10X imidazole buffer (500 mM imidazole, 180 mM 
MgCl2, 50 mM DTT), 150 picomoles of ATP, 10 /xl of a 24% (w/v) PEG 8000 
solution in a total reaction volume of 42 /xl. The reactions were incubated at 37°C 
for 45 minutes. After incubation 1 /xl of a 500 mM EDTA was added to stop the 
kinase reaction. The DNA was extracted with an equal volume of chloroform 
followed by ethanol precipitation. The DNA was resuspended in 15 /xl of TE buffer 
(pH 8.0) and quantitated by absorbance at 260 nm.
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Molar ratios were calculated for the plasmid vector and for the individual VP 
DNA fragments before setting up the ligation reactions. For the VP ligation 
reactions molar ratios ranging from 1:1, 2:1, 4:1 and 10:1 insert to vector were 
assayed. Ligation reactions containing 1 - 3  Units of the T4 DNA Ligase (GIBCO 
BRL, Gaithersburg, MD) in a 5X DNA ligase reaction buffer (250 mM Tris-HCl, 
pH 7.6, 50 mM MgCl2, 5 mM ATP, 5 mM DTT, and 25% (w/v) PEG 8000) were 
prepared in volumes of 10 or 15 microliters. In some experiments, the 
concentration of the PEG 8000 was increased to a final concentration of 14% to 
enhance the blunt-ended ligation and the cloning of the PCR products. The 
reactions were incubated overnight at 16°C followed by a 37°C incubation for 30 
min. Incubation at 35°C was also assessed for the overnight ligation. After 
incubation, the ligation reactions were diluted fivefold in a 10 mM Tris-HCl, pH 
7.5, 1 mM EDTA buffer. A fifth of the ligation mixture volume (15 /xl) was used 
as the standard for the transformation experiments, however different volumes were 
assessed depending on the concentration of the DNA in the ligation mixture.
The Escherichia coli strain GW1000 was selected for the transformation and 
amplification of the recombinant plasmids. To prepare competent cells for 
transformation, a 500 /xl from an overnight culture was diluted in 25 ml of fresh LB 
broth and the cells were incubated at 37°C for 2-2.5 hours with vigorous shaking. 
After incubation, the culture was centrifuged at 3,000 x g for 15 min at 4°C. The 
cells were resuspended in 20 ml of ice cold 100 mM CaCl2 and centrifuged again. 
After centrifugation the cells were resuspended in 10 ml of the CaCl2 and incubated
in ice for 45 min to 1 hour. After incubation the cells were centrifuged at 3,000 x g 
for 15 min and resuspended in 2 ml of the ice cold 100 mM CaCl2. The cells were 
stored at 4°C overnight before the transformation. For the transformation 200 /xl of 
competent cells were mixed with 15 /xl of the diluted ligation mix. The ligation 
mixture was incubated on ice for 30 minutes and then heat shocked at 42°C for 2 
minutes. After the transformation, one ml of SOC medium (2% tryptone, 0.5% 
yeast extract, 8.5 mM NaCl, 25 mM KC1, 10 mM MgCl2, 20 mM glucose, pH 7.0) 
was added and the cells were incubated at 37°C for 2-3 hours. The uncut plasmid 
vector was used as a control to monitor the transformation efficiency. After 
incubation 200 /xl of the transformed cells were plated onto SOC containing 
ampicillin (100 /ig/ml). The transformed cells were plated in triplicates (total 600 
/xl), and incubated at 37°C overnight. The remaining ligation mixture was stored at 
25°C and plated the next day. Representative colonies from each ligation ratio were 
selected and amplified in 10 ml of SOC-AMP for plasmid isolation and analysis.
Plasmid isolations were performed by the alkaline lysis method, which is a 
variation of the method of Birnboim and Doly (6) and Ish-Horowicz and Burke (43). 
Plasmid DNA was quantitated by measuring the absorbance at 260 nanometers. To 
confirm the size of the cloned DNA fragment the plasmid DNA was digested with 
an Apal restriction endonuclease. The size of the linearized plasmid DNA was 
compared with the size of the control plasmid, pTTQ18 digested with the same 
restriction endonuclease. A shift in the position of the linearized plasmid DNA 
corresponding to approximately 899 base pairs for VP1, 660 base pairs for VP2,
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and 737 base pairs for VP3, was interpreted as successful cloning of the amplified 
viral DNA. To finally confirm the cloning of the PCR fragments, the plasmid DNA 
from the specific recombinant plasmid DNA was used for PCR amplification using 
the corresponding primers for the VP1, VP2, or VP3 genomic regions. The 
reaction conditions were followed as mentioned before in the amplification of the 
specific VP regions. Amplification of VP fragments corresponding to the predicted 
molecular weight of the specific genomic fragments confirmed the cloning into the 
plasmid vector.
Expression and Detection of Beta-galactosidase Fusion Proteins:
Recombinant clones previously screened by restriction endonuclease analysis were 
assessed for the expression of the fusion products by the method of Stark (80). 
Briefly, each specific clone was grown overnight at 37°C in LB medium containing 
100 ixg ampicillin/ml and 0.5% glucose. Cells were subcultured into 50 ml of fresh 
LB-AMP-glucose medium. Cells were incubated at 37°C with vigorous shaking to 
an absorbance of 0.5 units at 600 nanometers. The cells were centrifuged at 3,000 x 
g for 5 min and resuspended to the original volume in pre-warmed LB medium 
containing 100 ^tg/ml of ampicillin. An aliquot of 10 ml was transferred to a sterile 
50 ml Erlenmeyer flask and the first 1ml aliquot (T0) was collected. To induce 
expression of the fusion product, 18 fd of a 0.5 M stock of isopropylthio-/3-D- 
galactosidase (IPTG) were added for a final concentration of 1 mM for pTTQ18 or 
1.3mM for pAX4b + . Cultures were incubated at 37°C with vigorous shaking and
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aliquots were withdrawn every hour for up to five hours after addition of the IPTG. 
At each time point during the incubation (i.e., 1, 2, 3, 4, and 5 hours), 1 ml of each 
culture was transferred to a microfuge tube and centrifuge at 12,000 rpm for 2 
minutes at room temperature. The supernatant was removed by aspiration. The cell 
pellet was resuspended in 100 /xl of a SDS gel-loading buffer (50 mM Tris-HCl, pH
6.8, 100 mM dithiothreitol (DTT), 2% SDS, 0.1% bromophenol blue, 10% 
glycerol), and heated to 100°C for 3 minutes. After heating, the tubes were 
centrifuged at 11,750 x g for 2 minutes at room temperature. Tubes were stored at 
-40°C until used.
Labelling of Plasmid-Encoded Proteins by the Maxicell System: The
method of Stoker et al. (85) was followed to confirm the expression of the VP1,
VP2 and VP3-plasmid encoded proteins. Each recombinant plasmid and the original 
pTTQ18 were separately transformed into the Escherichia coli strain CSR603 by the 
standard calcium chloride method mentioned before. Transformants were plated in 
SOC plates containing ampicillin as described previously. One colony of each 
transformant was inoculated into 3 ml of modified M9 medium (0.043 M 
Na2HP04T2H20 , 22 mM KH2P 04, 8.5 mM NaCl, 19 mM NH4C1, 1% casamino 
acids, 100 /xl of 0.5 M CaCl2, 5 ml of 0.1 M MgS04, 2.5 ml of 40% glucose, 250 
/xl of 1% thiamine), containing ampicillin (100 /xg/ml). The cultures were incubated 
overnight at 37°C. After incubation, 20 ml of modified M9 media containing 
ampicillin were inoculated with 1 ml of the overnight culture (20-fold dilution) and
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incubated in a 250 ml T-flask. The cultures were incubated at 37°C in a shaker 
incubator with vigorous agitation. Incubation was continued until the cultures 
reached the mid-log phase with an absorbance of 0.5 units at 450 nanometers. After 
incubation, two aliquots of 10 ml each of the culture were transferred to two 
separate sterile glass petri dishes. The aliquots were irradiated with ultraviolet light 
(254 nm) to a dose of 50 Joules/m2. After irradiation, the two 10 ml aliquots were 
pooled in a sterile 250 ml Erlenmeyer flask and incubated with shaking at 37°C for 
1 hour. After incubation, 100 fxl of a 40 mg/ml stock of D-cycloserine were added 
to each 20 ml culture for a final concentration of 0.2 mg/ml. The cultures were 
incubated at 37°C overnight with vigorous shaking. Following overnight incubation, 
the cells were centrifuged at 3,000 x g for 15 min and washed twice with 20 ml of 
a modified Hershey salts (0.6 mM KH2P 0 4, 21 mM NH4C1, 40 mM KC1, 92 mM 
NaCl, 100 mM Tris, pH 7.4, 10 ml of an amino acid stock (1% threonine, 1% 
leucine, 2% proline, 2% arginine), 1 ml of 1% thiamine, 1 ml of 40% glucose, 200 
jul of 0.5 M CaCl2, 1 ml of 1 M MgCl2). After washing, the cells were resuspended 
in 5 ml of the modified Hershey salts and transferred to a sterile 15 ml centrifuge 
tube (Corning Incorporated, Corning, NY). The cells were incubated at 37°C for 1 
hour in a rotary wheel incubator. After the incubation 35S methionine was added to 
a final concentration of 5 /^Ci/ml and the cells were incubated for an additional 
hour. After incubation the cells were centrifuged and resuspended in 100 /xl of a 
0.05 M Tris-HCl, pH 7.5, and stored at -20°C. To prepare the labelled cells for 
SDS-PAGE, a volume of 5 /xl of the cells previously resuspended in the Tris-HCl
buffer were mixed with 20 /xl of SDS-sample loading buffer (0.5 M Tris-HCl, pH
6.8, 10 ml; 10% SDS, 84 ml; bromophenol blue, 10 mg; glycerol, 8 ml; distilled 
water, 34 ml; and 2-/3-mercaptoethanol to a final concentration of 5% added before 
use). The suspension was boiled for 5 min and centrifuged for 5 seconds. The 25 
(xl sample was applied to the stacking gel of a discontinuous, 1 mm 12% 
polyacrylamide gel (48), and electrophoresed under constant current conditions at 18 
milliamperes in a Mighty Small R280 electrophoresis apparatus (Hoeffer Scientific 
Instruments, San Francisco, CA). The cell lysates were electrophoresed until the 
leading dye reached the bottom of the gel or about 5 to 6 hours. After 
electrophoresis, the gel was stained overnight in a 0.05% Coomassie blue, 10% 
acetic acid, 25% isopropyl alcohol solution with a gentle rocking motion. The 
staining step was followed by 4 to 6 hours of destaining in a 12.5% isopropyl 
alcohol, 10% acetic acid solution. After the destaining period, the solution was 
replaced by distilled water and continued to the gentle rocking motion for another 
hour. The water was then replaced for a 0.5 M salicylic acid solution and placed 
b&ck to the rocking platform for one hour. Next, the gel was placed in a piece of 3 
mm paper (Whatman LabSales, Hillsboro, OR) and dried for one hour at 60°C.
The dried gel was placed in an autoradiography cassette in direct contact with a 
piece of Kodak XOMAT-AR fluorography film (Eastman Kodak Company, 
Rochester, NY), and placed at room temperature for two to three days.
Development of the X-ray film was performed according to the manufacturer 
instructions.
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SDS-PAGE Analysis of Fusion Products: Beta-galactosidase fusion 
products expressed after induction with 1 mM or 1.3 mM IPTG were analyzed by 
SDS-PAGE in 7.5% and/or 12% discontinuous polyacrylamide gels of 1.5 mm 
thickness (48). Electrophoresis was performed at constant current at 18 
milliamperes for 4 to 5 hours in a Mighty Small R280 electrophoresis apparatus 
(Hoeffer Scientific Instruments, San Francisco, CA). Gels were stained using a 
Coomassie blue staining solution (0.25% Coomassie Brilliant Blue R-250, Sigma 
Chemical Co., St. Louis, Mo., 40% methanol, 7% acetic acid) for 3 to 4 hours with 
gentle shaking. After staining, the gels were destained for one hour in a destaining 
solution I (50% methanol, 10% acetic acid), followed by a destaining solution II 
(5% methanol, 7% acetic acid) for 4 to 6 hours.
Western Blot Analysis of Fusion Products: Polyacrylamide gels intended
for Western Blot analysis were electrophoresed under the conditions mentioned 
above. After electrophoresis the gels were equilibrated for 30 minutes in 500 ml of 
a Tris-glycine transfer buffer (25 mM Tris, pH 8.3, 192 mM glycine, 20% v/v 
methanol). During the equilibration period filter pads, 3 mm Whatman filter paper 
(Whatman LabSales, Hillsboro, OR), and nitrocellulose paper of the same 
dimensions of the polyacrylamide gel were saturated with the Tris-glycine transfer 
buffer. After saturation of all the components of the blot, a saturated filter pad is 
placed on the inner side of the gel holder. A saturated piece of filter paper is placed 
on top of the pad followed by the pre-equilibrated gel. The gel was pressed against
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the filter paper support by rolling a glass pipet on the surface of the gel to remove 
any trapped air bubbles. Next, a piece of saturated nitrocellulose membrane was 
placed on top of the gel and trapped air was removed again as indicated above.
This was followed by a saturated filter paper, removal of air bubbles, and a piece of 
saturated filter pad. The gel holder was closed and the assembled gel-membrane 
sandwich was placed in the Trans-Blot™ Cell (BioRad Laboratories, Richmond, CA), 
with the nitrocellulose to the anode side. Transfer onto nitrocellulose was 
performed overnight under low field, uncooled conditions (30V/0.1A) with constant 
stirring. After the overnight transfer, a standard field 2 hour transfer was performed 
at 60V/0.21A. For immunoscreening of the expressed fusion products, the 
Protoblot Immunoscreening System (Promega, Madison, WI) described in the 
Promega Protocols and Applications Guide was followed (69). Nonspecific protein 
binding sites on the blotted nitrocellulose paper were saturated by incubating the 
filters in TBST-1% BSA (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% 
Tween20). The nitrocellulose filters were incubated for 30 minutes at room 
temperature with gentle shaking. After blocking, the filters are incubated for 30 
minutes in TBST containing the primary antibody (rabbit-anti HAV; mouse-anti 
HAV, mouse monoclonal antibody). The primary antibody from polyvalent sera 
were diluted 1:1,000 and incubation was performed at room temperature. After 
incubation, the nitrocellulose membranes were washed 3 times in 15-20 ml of TBST 
for 5-10 min each wash. The nitrocellulose membranes were transferred to TBST 
containing an appropriate dilution of an alkaline-phosphatase conjugated secondary
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antibody (Cappel/Organon Teknika Corp., West Chester, Pa). The secondary 
antibody is incubated for 30 minutes at room temperature. The filters are then 
washed three times as mentioned before, and the nitrocellulose membranes are then 
blotted onto a piece of filter paper to remove excess buffer. Damp membranes are 
transferred to a freshly prepared alkaline-phosphatase (AP) color development 
substrate solution. (5ml AP buffer: 100 mM Tris-HCl, pH 9.5, 100 mM NaCl, 5 
mM MgCl2, 33 /xl of nitroblue tetrazolium (50 mg/ml), 16.5 /xl 5-bromo-4-chloro-3- 
indoyl phosphate (50 mg/ml)). Development of the color reaction was monitored 
for up to four hours avoiding over exposure and high non-specific background. The 
development reaction was stopped by replacing the substrate development solution 
with a stop solution (20 mM Tris-HCl, pH 8.0, 5 mM EDTA) and rinsing the filters 
in two or three volumes of the stop solution. The filters were placed on a piece of 
filter paper to remove excess stop buffer and the damp filters were stored inside 
individual filter paper envelopes in the dark.
Treatment of Rabbit Antisera for Western Blot Analysis: A cyanogen 
bromide-activated Sepharose 4B matrix (Sigma Chemical Co., St. Louis, Mo.) was 
constructed to remove endogenous rabbit antibodies directed against E. coli proteins. 
The affinity column was constructed using the commercially available E. cob protein 
extracts (Promega, Madison, Wi). A total of 2.6 grams of the activated CNBr- 
Sepharose were weighted and allowed to swell in 50 ml of 1 mM HC1 for 15 
minutes. After swelling, the gel was transferred to a 50 ml conical-screw capped
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centrifuge tube and washed several times with a total of 500 ml of the 1 mM HC1. 
For each wash, the Sepharose was centrifuged at 180 x g for 1 min and the 
supernatant was removed. Before coupling the E. coh lysate to the solid matrix, the 
bacterial lysate was dialyzed overnight against a 0.1 M carbonate buffer, pH 8.3, 
containing 0.5 M NaCl. A total of 88.4 mg of the bacterial lysate were added to the 
activated Sepharose. The protein solution was mixed with the gel suspension in the 
screw-capped conical centrifuge tube. The incubation was carried out for two hours 
at room temperature and then overnight at 4 °C in an end-over-end mixing platform. 
After incubation, the remaining active groups in the CNBr-Sepharose matrix were 
blocked by resuspending the gel in a 0.2 M glycine solution, pH 8.0. The 
resuspended gel was incubated overnight at 4°C using the mentioned mixing 
platform. After the blocking step, the gel was washed to remove uncoupled ligand 
and blocking glycine. Alternate washes were performed with the 0.1 M carbonate 
buffer, pH 8.3, containing 0.5 M NaCl and with a 0.1 M acetate buffer, pH4.0, 
also containing 0.5 M NaCl. The matrix was washed five times with each of the 
buffers. The gel was then packed in an 8.0 ml column (Pierce, Rockford, IL), and 
washed with a 0.1 M phosphate buffer containing 0.01% thimerosal. The column 
was stored at 4°C until needed.
Expression of Beta-Galactosidase Fusion Peptides: Large scale production 
of the fusion peptides was accomplished by a combination of the protocols of Stark 
(84) and the Induction of j8-Galactosidase Fusion Products as described in the
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Promega Protocols and Applications Manual (69). Bacterial clones containing the 
recombinant plasmids encoding for the fusion VP peptides were inoculated onto LB 
medium containing 100 /ig/ml of ampicillin and 0.5% glucose. The overnight 
cultures were used to inoculate fresh LB-ampicillin media containing glucose. The 
cells were grown at 37°C in a shaker incubator to an optical density of 0.5 units at a 
wavelength of 600 nanometers. At this point the cells were centrifuged at 5,900 x g 
for 15 minutes. The cell pellets were resuspended to the same density in LB media 
containing ampicillin (100 pg/ml), but no glucose. To induce expression of the 
recombinant plasmid, the inducer IPTG was added to a final concentration of 1 mM 
for the plasmid pTTQ18 or 1.3 mM for the plasmid pAX4b +  . The cells were 
incubated at 37°C in a shaker incubator for five hours. After the induction period, 
the cells were centrifuged at 5,900 x g for 15 min. and the cell pellet was 
resuspended in 30 ml of a 100 mM Tris-HCl, pH 7.4, 10 mM EDTA, 1 mM phenyl 
methyl sulfonyl fluoride (PMSF). The resuspended cells were transferred to a 
Model 25 Rosett Cooling Cell (Heat Systems Co., Melville, L.I.) and disrupted by 
ultrasonic treatment in a Sonifier cell disrupter W350 (Branson Sonic Power Co., 
Danbury, Conn.). Fifteen sonication cycles of 45 seconds each were performed at a 
setting of 200 watts. The cell suspension was centrifuged at 5,900 x g for 15 min to 
remove cell debris and the supernatant was transferred to an Erlenmeyer flask. The 
sonication cycles were repeated three more times after resuspending the cell pellet in 
10 to 20 ml of the TEP buffer. The total volume of the supernatant was quantitated 
and the total protein was precipitated by a 75% ammonium sulfate fractionation.
After slow addition of the ammonium sulfate, the mixture was stored at 4°C 
overnight. Next, the protein precipitate was centrifuged at 5,900 x g for 15 min. 
and the pellet was resuspended in 50 ml of TEP buffer (100 mM Tris-HCl, pH 7.4, 
10 mM EDTA, 1 mM PMSF). The total protein concentration was determined by 
the BCA method (Pierce, Rockford, IL.) and stored at 4°C until needed for 
application to the immunosorbent column.
Anti-HAV Immunosorbent Matrix: Rabbit anti-HAV antibody was 
immobilized to a Protein A Sepharose matrix following the method of Schneider 
et.al. (79). Rabbit polyvalent serum generated against the HM175 strain of the 
Hepatitis A virus was absorbed through the Sepharose 4B column previously linked 
to the E. coli protein cell lysate. The absorbed serum was then fractionated in a 
40% ammonium sulfate precipitation three consecutive times. The precipitated 
immunoglobulins were resuspended in a small volume of 0.1 M borate buffer, pH
8.2, and dialyzed against an excess of the borate buffer to remove any residual 
ammonium and sulfate ions. A total of 0.5 grams of Protein A Sepharose were 
washed several times with the 0.1 M borate buffer, pH 8.2. An equivalent of 12 
milligrams of the previously fractionated anti HAV immunoglobulins in borate 
buffer were mixed with 1 ml of the washed Protein A Sepharose matrix. The 
mixture was allowed to incubate for 30 minutes at room temperature with gentle 
shaking in a rotary shaker. After the incubation, the IgG-immobilized Protein A 
Sepharose matrix was washed several times with 10 volumes of the 0.1 M borate
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buffer. The matrix was then washed once with a 0.2 M triethanolamine buffer, pH
8.2. After the triethanolamine wash, the matrix was resuspended in 20 volumes of 
dimethyl-pimelimidate-dihydrochloride which was prepared before use in 0.2 M 
triethanolamine taking into precaution to quickly readjust the pH to 8.2 units. The 
mixture was gently mixed at 60 rpm in a rotary shaker for 45 minutes at room 
temperature. After incubation, the reaction was stopped by centrifugation at 180 x g 
for one minute and resuspension of the cross linked Protein A Sepharose in an equal 
volume of 0.05 M ethanolamine, pH 8.2. After five minutes, the cross-linked beads 
were washed several times in the 0.1 M borate buffer, pH 8.2. After the last wash, 
the IgG linked Protein A Sepharose was packed in a column (Pierce, Rockford, IL.) 
and washed with a 0.05 M diethylamine elution buffer, pH 11.5, to remove any 
unbound protein. After the elution buffer, the matrix pH was reconstituted to pH 
8.2 with a 0.067 M borate buffer saline. At this point the column is ready for 
application of the fractionated cell lysate prepared in the previous section. Elution 
of proteins was monitored by their absorbance at 254 nanometers (Gilson Model 
111, Middleton, WI.). The protein lysate was diluted in 50 mM Tris-HCl buffer, 
pH 8.2, to a concentration of approximately 4 mg/ml for application to the affinity 
column. For elution of non-specific material, the column was washed in sequence 
with two to three volumes of the following buffers; wash A (50 mM Tris-HCl, pH
8.2, 500 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40), wash B (50 mM Tris-HCl, 
pH 8.2, 150 mM NaCl, 0.5% Nonidet P-40, 0.1% SDS), wash C (150 mM NaCl, 
0.5% sodium deoxycholate). Bound material was eluted with two volumes of a 50
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mM diethylamine, pH 11.5, 0.5% sodium deoxycholate buffer collecting the eluate 
directly into a dialysis bag immersed in borate buffered saline (0.67 M H3B 03, pH 
8.4, 0.15 M NaCl), to neutralize the eluted peptides immediately. After dialysis, 
the peptides were concentrated with a carboxymethyl-cellulose adsorbent 
(AQUACIDE) (CALBIOCHEM Corp., La Jolla, CA).
Anti-Beta-Galactosidase Affinity Purification of Fusion Peptides: 
Purification of the fusion peptides was also assessed with a commercial anti-/3- 
Galactosidase affinity matrix (Promega Corp., Madison, WI). The protein lysate 
obtained after ammonium sulfate fractionation and resuspended in TEP buffer was 
diluted in Tris buffer (50 mM Tris-HCl, pH 7.3) to a concentration of 4 mg/ml. 
Aliquots of 10 to 15 ml were applied to the gel matrix which had been previously 
equilibrated with the Tris buffer. Flow rate was adjusted to approximately 1 ml per 
10 to 15 minutes. After loading, the column was washed with five volumes of TN 
buffer (50 mM Tris-HCl, pH 7.3, 0.2% Nonidet P-40). The bound protein was 
eluted with four to five volumes of a 0.1 M NaHC03/Na2C 03, pH 10.8. The eluted 
fraction was neutralized by collecting directly into a dialysis bag immersed in borate 
buffered saline (0.67 M H3B 03, pH 8.4, 0.15 M NaCl). The dialyzed peptides were 
concentrated with a carboxymethyl cellulose adsorbent. The total protein 
concentration was determined by the BCA method (Pierce, Rockford, IL), and the 
pure peptides were analyzed by SDS-PAGE and Western Blot analysis.
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Cleavage of Beta-Galactosidase Fusion Proteins: Cleavage of the fusion 
proteins was performed by two methods. In the first, a clostridiopeptidase purified 
from Clostridium hystoliticum (United States Biochemical Corp., Cleveland, OH) 
was used following the protocols described by the manufacturer and by Bond and 
Van Wart (10). A 10X collagenase buffer (500 mM Tris, pH 7.5, 500 mM glycine, 
4 M NaCl, 100 mM CaCl^) was added to an aliquot containing 100 fig of the 
previously concentrated fusion peptide. Four units of a freshly prepared collagenase 
enzyme in 4 /x\ of a IX collagenase buffer were added. The mixture was incubated 
at 37°C for 30 min. After incubation, an equal volume of the 2X SDS gel-loading 
buffer (100 mM Tris-HCl, pH 6.8, 200 mM DTT, 4% SDS, 0.2% bromophenol 
blue, 20% glycerol), was added. The samples were boiled for 3 min and then 
centrifuged at 12,000 x g for 2 min. After centrifugation, the samples were 
resolved by SDS-PAGE, stained with Coomassie blue or analyzed by Western Blot.
In the second approach, an endoproteinase Xa (from Bovine blood coagulation 
factor X), (United States Biochemical Corp., Cleveland, OH) was used to assess the 
cleavage of the fusion peptides following a modification of the method described by 
Nagai and Thogersen (59). Cleavage of the fusion peptides was assessed at 4°C,
25°C, and 37°C in a 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM CaCl2 
reaction buffer containing 1 % urea. Aliquots of 0.5 to 1.0 ml of the affinity- 
purified fusion peptide were dialyzed in 500 ml of the buffer until the assay 
temperature was reached. Once the temperature was reached, the endoproteinase Xt 
was added at an enzyme to substrate molar ratio of 1:50. The digestion reaction
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was incubated for 8, 12, or 24 hours for the assessment of the optimal conditions for 
the peptide cleavage. After incubation, an equal volume of the 2X SDS loading 
buffer was added and the samples were boiled for 3 min followed by centrifugation 
at 12,000 x g for 2 min. The samples were resolved by SDS-PAGE and stained 
with Coomassie blue or analyzed by Western Blot.
RESULTS
Two strategies were followed before amplification of the individual genes 
encoding for the viral capsid peptides. In the first, the viral RNA was isolated by 
the Method of Chomczynski and Sacchi (12) from a total of 5 X 109 virions, as 
mentioned in the viral RNA isolation section in the previous chapter. A genomic 
region of approximately 2.4 kilobases comprising the genes encoding for the viral 
capsid peptides VP1, VP2, and VP3, was selected for reverse transcription followed 
by PCR amplification. After two unsuccessful attempts, the approach was 
abandoned since this effort was compromising the limited source of Hepatitis A 
virus which was also required for animal immunization and immunoscreening MAb 
from hybridomas. Effective amplification of a smaller genomic region of the HAV 
genome was accomplished for a sequence located in the carboxy terminus of the 
gene encoding for the capsid peptide VP3. This sequence of 191 nucleotides was 
successfully amplified through 90 automated cycles.
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In the second approach, amplification of the 2.4 kilobase region and/or each 
individual capsid gene was performed from the plasmid pGEM-HAV. This plasmid 
contained the wild type HAV HM-175 cDNA minus an Apal fragment of 
approximately 562 base pairs (13). The plasmid was amplified in the presence of 
ampicillin (100 ug/ml) and the DNA was purified by the alkaline lysis method (6, 
43). The oligonucleotide primers OP2/RT1 and DC1/DC2 were used in separate 
reactions for amplification of the 2.4 Kb-Pl viral genomic region, and the 191 
nucleotide VP3 carboxy region respectively. Amplification reactions which 
contained 220, 22, 2.2, and 0.22 nanograms of the pGEM-HAV DNA were 
subjected to 30 automated cycles. Amplification of the 2.4 Kb region was obtained 
at the 220, 22 and 2.2 nanogram concentrations of the plasmid template. 
Amplification at the 0.22 nanograms was not as efficient and a much lower quantity 
of the 2.4 Kb product was recovered, a finding not unexpected since the plasmid 
template concentration was below the low limit of 1.0 nanogram recommended by 
the manufacturer of the PCR amplification kit. For the DC1/DC2 reaction, effective 
amplification was obtained in the 220 and 22 nanogram template concentrations. 
Amplification was also obtained for the 2.2 and 0.22 nanogram concentrations, 
however recovery levels reflected a much lower amplification for these two reaction 
systems.
Specific oligonucleotide primers were designed for the selective amplification 
of individual genes encoding each capsid peptide. The primers are depicted in 
Figure 5. The nucleotide sequence reported by Cohen et al. (14) was used to select
sequences internal to the individual capsid sequences and design oligonucleotide 
primers. The PCR products generated from the first round of amplification for each 
capsid gene consisted of blunt-ended products. Prior to cloning the PCR fragments, 
the plasmid vector pTTQ18 shown in Figure 6 was digested at the ZicoRI and 
Hindlll sites within the polylinker region of the plasmid. A fragment of 55 base 
pairs was removed from the polylinker region of the 4,563 base pair plasmid. The 
resultant cohesive ends following restriction enzyme digestion of the plasmid were 
blunt ended by treatment with a mung bean nuclease enzyme, followed by treatment 
with calf intestinal alkaline phosphatase to avoid re-annealing of the blunt ended 
plasmid.
The initial ligation experiments for the blunt-ended products were performed 
on a molar-based ratio of insert to vector at 1:1, 2:1, and 10:1 under conditions 
specified in the materials and methods section. The DNA was mobilized into the 
host strain Escherichia coli GW1000 by electroporation following the protocol 
provided by the manufacturer (BioRad, Richmond, CA), and also by standard 
calcium chloride transformation. No recombinant colonies were obtained by either 
method following plating the cultures on LB-AMP media. Control ligations were 
performed with the plasmid vector alone after digestion with restriction 
endonucleases that generated blunt ends (Smal) or with endonucleases that generated 
cohesive ends (EcoRI, Hindlll) that were blunt-ended after nuclease treatment.
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V P - l -P S
5’ GTT GGA GAT GAT TCT GGA
V P - l -N S
5’ T CTC AAA TCT TTT ATC TTC
V P -2 -P S
5’ GAC ATT GAG GAA GAG CAA
V P -2 -N S
5’ T TTG TGT AGA AAG AGG AGT
V P -3 -P S
5’ ATG AGA AAT GAA TTT AGG
V P -3 -N S
5’ T TTG TGT AGT AAC ATC CAT
Figure 5: Oligonucleotide primer sequences designed for PCR amplification and 
blunt-ended cloning of HAV capsid genes. (VP) viral peptide, (PS) 
positive strand primer, and (NS) negative strand primer.
92
a t G A A T T C g a g c t c g  . . .  MCS . . .  c a t g c A A G C T T g c c a
t a C T T A A G ctcgagc  . . .  . . .  gtacgT T C G A A cggt
Eco R1 Hindlll
a t G A A T T C ga g ctc g g ta c cc g g g g a tc c tcta g a g tc g a c c tg c a g g ca tg cA A G C T T ggca
^  /o cz
pTTQ18 
4 5 6 3  bp
amp
Figure 6: Prokaryotic expression plasmid pTTQ18. Restriction endonuclease sites 
EcoRI and Hindlll were selected for digestion and cloning of blunt-ended 
PCR products after treatment of the plasmid DNA ends with the Mung 
Bean nuclease enzyme. The general features illustrated in the figure 
include a hybrid trp-lac (ptac) promoter, polylinker region (MCS), 
lacZcx coding region (lacZ), transcription terminator from E. coU rrnB 
operon (rrnBt!12), lac repressor gene (lacfi) , ampicillin resistance 
marker (amp).
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Limited success was obtained with the re-ligation of the blunt ended DNA 
after digestion by the first approach. Attempts were made to re-anneal the blunt 
ends generated by MB nuclease treatment of the EcoRl-Hitidlll digested plasmid and 
they were unsuccessful. These findings suggested difficulties in the generation of 
blunt ends by the MB nuclease enzyme. Several different parameters in the ligation 
reaction were examined in an attempt to determine the cause for failure to clone the 
PCR products, and they include: phosphorylation of the blunt-ended PCR fragments 
with a T4 polynucleotide kinase before cloning, the incubation temperature for the 
overnight ligation reaction, introduction of additional polyethylene glycol PEG 8000 
to enhance the ligation of the blunt ends, increases in the T4 ligase units from 1 to 3 
Units, and various DNA concentrations at the molar ratios mentioned above were 
assessed in several experiments. No recombinant colonies (carrying the viral capsid 
genes) were obtained although re-ligation of the plasmid vector occurred on a few 
occasions. Mobilization of DNA into bacterial cells did not present any difficulties 
since electroporation or transformation of the uncut plasmid vector always produced 
transformants. At this juncture, the blunt-ended ligation approach for the cloning of 
the viral genes was abandoned.
The cloning approach described by Huse et al.(42), and Orlandi et al.(63) 
was used as an alternative to overcome the difficulties confronted with the blunt- 
ended ligation. The oligonucleotide primers shown in Figure 7 were, designed to 
flank the ends of the genes of interest for PCR amplification. These oligonucleotide 
primers contained selected restriction endonuclease sequences that once incorporated
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into the amplified PCR product will facilitate the forced and directional cloning into 
the plasmid vector. The oligonucleotide primers were designed with the 
consideration not to select restriction sites internal to the viral capsid sequence since 
this would result in digestion of the viral capsid gene instead of generating the 
required cohesive ends for the cloning step. Care was also taken to avoid selection 
of restriction enzymes that are deficient digesting sequences near extreme ends of 
PCR products as previously reported by Kaufman and Evans (46). In the design of 
the oligonucleotide primers it was essential to position the cloning site in concert 
with the restriction endonuclease sites in the correct 5 ’ and 3’ frame to allow 
expression of the cloned gene, and avoid a frameshift. Figures 8a and 8b outline the 
cloning approach. Following restriction endonuclease treatment of the PCR products 
to generate the cohesive ends the DNA was recovered by utilization of a Geneclean 
DNA purification kit (Bio 101 Inc., LaJolla, CA). This approach permitted for the 
selective binding and purification of DNA fragments above a 200 base pair size and 
excluded smaller ends that might compete for complementary sequences in the 
ligation reaction. This purification protocol was also used to eliminate the 55 base 
pair EcoRl-Hindlll fragment of the plasmid DNA. Figure 9 shows the PCR 
products for the VPO, VP1, VP2, and VP3 generated through 30 automated cycles.
The first cloning attempt was done with the VP1 amplified product. The 
ligation conditions used were molar ratios of insert to vector 1:1, 2:1, and 4:1, with 
vector concentrations of 100 nanograms to 600-nanograms. Overnight incubation at 
16°C followed by 37°C for 30 min was followed for each ligation reaction in a
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P S - l- is c o
5’ CCG AAT TCT GTT GGA GAT GAT TCT GGA
Eco RI
NS-l-H ind
5’ CCA AGC TTC CCT CAA ATC TTT TAT CTT C
Hind III
PS-2-Eco
5’ CCG AAT TCG GAC ATT GAG GAA GAG CAA
Eco RI
N S -2 -Hind
5’ CCA AGC TTT GTG TAG AAA GAG GAG T
Ilind  III
P S -3 -£ c 0
5’ CCG AAT TCT ATG AGA AAT GAA TTT AGG
Eco RI
N S -3  -Bam
5’ CCA GGA TCC CCT TGT GTA GTA ACA TCC AT
Ham III
Figure 7: Oligonucleotide primer sequences containing restriction endonuclease 
sequences designed directional-forced cloning of PCR amplified HAV 
capsid genes. (PS) positive strand primer, (NS) negative strand primer, 
(1) VP1, (2) VP2, (3) VP3.
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a t G A G C T T gcca
t a C T T A A  A cggt
Eco R I Hindlll
a t G A G C T T ggca
!ocZ
pTTQ18 
4 5 6 3  bp
amp
F igure  8a: Restriction endonuclease digestion of the expression vector pTTQ18 
with specific restriction endonucleases. The selection of different 
cohesive ends allowed for the directional and forced cloning of PCR 
products containing compatible ends.
Eco R1/Hind III d igest
Ligation to predigestedpTTQia







Figure 8b: Outline of the cloning approach followed for VPO, VP1, and VP2.
Cloning of the pre-digested restriction endonuclease-flanked PCR 
products was performed in separate events into the pre-digested vector.
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igure . 1% agarose gel of PCR-amplified HAV capsid genes. Lane 1: VPO (692 
bp), Lane 2: VP1 (899 bp), Lane 3: VP2 (665 bp), Lane 4: VP3 (737 
bp), and Lane 5: BioMarker low molecular weight standard.
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volume of 15 p\. Transformations were performed with DNA concentrations of 20 
nanograms to 120 nanograms DNA. The efficiency for recovery of VP1 
recombinant colonies was extremely low. For example, a ligation reaction using 
318 nanograms of the plasmid vector at a molar ratio of 2:1 produced only two 
recombinant colonies, which translated into an efficiency of less than one colony per 
100 nanograms of DNA compared to 167 recombinant colonies obtained when cells 
were transformed with the same quantity of uncut plasmid vector. Although, the 
low efficiency for the ligation reaction and the consequent recovery of recombinants 
was a matter for concern for future experiments, the cloning approach used ensured 
recovery of recombinant plasmids which contained the viral gene in the desired 
orientation. Each recombinant clone was expanded in LB-AMP media, the plasmid 
DNA purified, and subjected to restriction enzyme analysis to confirm successful 
cloning. An April or EcoRI restriction enzyme digest produced a linear DNA 
molecule of the predicted size, approximately 5.4 - 5.5 Kb. For the pTTQ18 
plasmid of 4,563 bp minus 56 bp (EcoRl-Hindlll fragment), plus 899 bp (the 
amplified VP1 gene), which accounts for the total of 5,406 base pairs.
For cloning of VP3 viral gene molar ratios of 2:1, 4:1, and 10:1 were used 
in the ligation reaction with 100 nanograms of vector DNA. As opposed to other 
cloning experiments in which EcoRI and Hindlll sites were selected, for VP3 
cloning experiments a BamHl restriction site was selected, because a Hindlll site 
internal to the VP3 gene is present. Transformation of competent cells was done 
with quantities from 20 to 100 nanograms of vector DNA, and recovery of
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recombinant colonies was higher than for VP1 experiments. An average of 81 
recombinants were obtained at the 2:1 ratio, 73 for the 4:1 ratio, and 41 for the 
10:1 ratio, and the uncut plasmid vector showed high recovery of transformants. 
Several of the expanded clones possessed the expected 5.2 Kb linearized 
recombinant plasmid after DNA isolation and restriction enzyme analysis. The size 
corresponded to approximately 4,538 base pairs after removal of the EcoRl/BaniRl 
fragment plus 737 base pairs for the amplified VP3 gene, which accounts for a total 
of 5,275 base pairs.
Cloning of the VP2 viral gene showed higher transformation efficiency than 
VP1 cloning but low when compared to the VP3 results. Molar ratios of 1:1, 2:1, 
4:1, and 10:1 were assessed in the ligation reaction using 100 nanograms of vector 
DNA. The recombinant plasmid DNA was isolated and analyzed by restriction 
endonuclease digestion, where a band of approximately 5.1 kb was expected.
Finally, the genomic region VP0 region was selected for amplification and 
cloning. This region ecompases the VP4 and VP2 viral capsid genes, adding 68 
nucleotides to the 665 nucleotide VP2 gene. Molar ratios of 1:1, 2:1, 4:1, and 10:1 
were assessed in ligation reactions performed using from 100 to 400 nanograms of 
the vector DNA. The number of recombinants obtained through antibiotic selection 
was comparable to numbers obtained for VP1. One to two recombinants obtained 
per 100 nanograms of vector DNA was calculated. Restriction endonuclease 
analysis of the recombinant plasmid was performed and a linearized plasmid size of 
approximately 5.2 kb was obtained.
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Successful cloning was determined by restriction enzyme analysis which 
generated a single cut in the recombinant plasmid DNA. Following agarose gel 
electrophoresis the size of the recombinant plasmid was compared to that of the 
original plasmid vector. An increase in the size of the linearized plasmid 
corresponding to the cloned fragment was considered as preliminary evidence of 
successful cloning. To confirm the amplified viral gene had been cloned, the 
recombinant plasmid DNA was subjected to PCR using the oligonucleotide primers 
specific for the gene of interest. If the gene was successfully cloned, a PCR product 
of the predicted size for the viral capsid gene should be amplified.
Following cloning and restriction endonuclease analysis of the recombinant 
plasmids containing Hepatitis A capsid genes, expression of the beta-galactosidase 
fusion peptides was assessed. The method of Stark (84) was used to determine 
plasmid expression when induced with 1.0 mM concentration of isopropylthio-/3-D- 
galactosidase (IPTG). Before analysis, the bacterial host was examined for 
expression of proteins for those cells that carried the plasmid and cells that did not 
contain the plasmid. Electrophoretic analysis of each bacterial lysate was done in 
12% discontinuous polyacrylamide gels. Figure 10 illustrates the electrophoretic 
profile for the background proteins for the host E. coh GW1000 strain. Lane 2 of 
the Coomassie blue-stained gel shows the electrophoretic pattern for lysates from the 
bacterial host strain (no plasmid). Timepoints were examined before the addition of 
the IPTG (T0) and at hour intervals after addition of the IPTG inducer. The right 
side panel illustrates the pattern for bacterial lysates for the host cell carrying the
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plasmid pTTQ18. Again, samples were collected at different timepoints after 
addition of the IPTG. The profiles reveal that the presence of the plasmid and/or 
the IPTG caused induction of protein expression other than beta-lactamase or the 
alpha-fragment of the /3-galactosidase enzyme. These two proteins express 
molecular weights of 30 kilodaltons (Kd) and 16 Kd respectively which originate 
from the expression plasmid. Protein bands are also observed above the 30 Kd 
molecular weight marker. The purpose of this preliminary analysis was to identify 
those protein bands which differ from those expressed by the cloned viral genes, and 
to ascertain the influence the plasmid and/or the IPTG exerts in the bacterial host. 
Induction and expression of recombinant pTTQ18-VPl was assessed. Figure 11 
shows the SDS-PAGE analysis for plasmid expression under IPTG induction. Lane 
2 shows the cell lysate before addition of inducer (T0) followed by one hour 
timepoint samplings following addition of the IPTG inducer (Tj - T5). A protein 
band appears after IPTG induction around the 49 Kd region and is indicated by the 
arrowhead. The size correlates with the predicted size of the alpha fragment of the 
/3-galactosidase (16 Kd) plus the VP1 capsid peptide (33 Kd). Although a protein 
band appeared with the expected molecular weight, the induction of the peptide did 
not seem to intensify as the induction time progressed. Western blot analysis of the 
SDS-PAGE gel did not reveal a definitive reaction when the blotted proteins were 
exposed to polyvalent rabbit antiserum raised against intact HM175 Hepatitis A 
virions. The primary difficulty confronted was appearance of "non-specific antibody 



















Figure 10: Comparison of E. coU GW1000 (left panel) against the recombinant
strain containing the plasmid TTQ18 (right panel). Cells were grown to 
A600 of 0.5. 1 ml aliquots were withdrawn before induction with ImM 
IPTG followed by 1 hour timepoints. Cells were resuspended in a 1 % 
SDS buffer and 80 fj.g of protein lysate were separated by 12% SDS- 
PAGE under constant current conditions. (lane 1, molecular weight 
marker; lane 2, E. cob GW1000 before induction with ImM IPTG; 
lane 3; 2 hr after induction; lane 4, 4 hr; lane 5, 6 hr; lane 6, E. coli 
GW1000-TTQ18 before IPTG induction; lane 7, 2 hr after induction; 
lane 8, 4 hr; lane 9, 6 hr; lane 10, molecular weight marker).
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protein band at the 49Kd. The non-specific background was reduced when 
antiserum was absorbed with a commercial E. coU cell extract (Promega, Madison, 
WI) but still exhibited poor expression for the fusion peptide which made it difficult 
to detect above the host background. No band developed when the monoclonal 
antibody P2-G9 was used in western blot analysis which suggested lack of 
expression of the fusion peptide.
Electrophoretic analysis of the recombinant pTTQ18-VP3 revealed a 
much higher level of expression upon induction with IPTG. Figure 12a shows the 
electrophoretic analysis of the cell lysated stained with coomassie blue. For the 
viral capsid peptide VP3 (molecular weight of 29 Kd) the expected fusion peptide 
of 43 Kd was detected. If the 16 Kd alpha-fragment was subtracted from the 
product obtained, a viral peptide of approximately 27 to 29 Kd results. The stained 
gel showed a strong induction evident from the first hour following IPTG addition, 
with reduced host background, which suggests protein expression from the plasmid. 
Western blot analysis of this fusion peptide with the anti-HAV rabbit antiserum 
detected a 43 Kd peptide, with minor non-specific background reaction (Figure 12b). 
Induction of the pTTQ18-VP2 recombinant plasmid showed poor or no expression of 
the fusion peptide, as previously observed for the pTTQ18-VPl. Figure 13 shows 
the electrophoretic analysis of bacterial lysates following induction of recombinant 
plasmid. Protein bands were detected at 49 Kilodaltons, which is a higher molecular 
weight than the expected VP2 fusion product of 40 kD. No detectable reaction was 
demonstrated by western blot analysis against the anti HAV serum.
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Figure 11: Regulation of expression from recombinant plasmid TTQ-VP1. Proteins 
from uninduced (lane 2), or induced bacterial cells (lanes 3-7) were 
examined by SDS-PAGE using a 12% gel. (lane 1, molecular weight 
marker: lane 2, cells before ImM IPTG induction: lane 3, 1 hr after 
induction: lane 4, 2hr: lane 5, 3 hr: lane 6, 4 hr: lane 7, 5 hr: lane 
8, molecular weight marker).
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Figure 12a: Regulation of expression from recombinant plasmid TTQ-VP3.
Proteins from uninduced (lane 2), or induced cultures (lanes 3-7) were 
examined by SDS-PAGE using a 12% gel. (lane 7, molecular weight 
marker: lane 2, cells before ImM IPTG induction: lane 3, 1 hr after 
induction: lane 4, 2hr: lane 5, 3 hr: lane 6, 4 hr: lane 7, 5 hr: lane 
8, molecular weight marker).
Figure 12a: Western blot analysis of expressed fusion peptides from recombinant plasmid pTTQ-VP3 against a rabbit polyvalent 
serum generated against the intact HAV. (Left panel) 12% SDS-PAGE from uninduced (lane 2), or induced bacterial 
cells (lanes 3-7). {lane 1, molecular weight marker: lane 2, cells before 1 mM IPTG induction: lane 3, 1 hr after 
induction: lane 4, 2 hr: lane 5, 3 hr: lane 6, 4 hr: lane 7, 5 hr: lane 8, molecular weight marker). (Right panel) 
Western blot of SDS-PAGE. (lane 2, uninduced cells: lanes 3-7, induced bacterial cells as in left panel: lane 8, 
Amersham Rainbow molecular weight marker).
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The failure to detect the fusion product with the polyvalent anti-HAV 
suggested a lack of expression of the fusion peptide or a low level of expression 
impossible to recognize because of non-specific background of anti-E. coli antibody 
activity.
Expression of only one of the fusion peptides motivated a closer examination 
of the nucleotide sequence for each gene encoding the viral capsid peptides. Besides 
the promoter sequence, ribosome binding site, and start codon, all of which were 
within the plasmid and therefore identical for each individual cloned viral gene, one 
peculiarity detected in the VPO and VP3 genes was the presence of additional AUG 
codons which when the viral genes were cloned in the plasmid vector resulted in 
tandem starting codons. This arrangement was not present in the VP1 and VP2 
genes which prompted consideration of introducing a similar arrangement in the 
these two genes with the purpose of enhancing gene expression. To pursue this 
objective, a positive strand oligonucleotide primer was designed for the VP2 gene. 
Figure 14 presents the rationale used to design the primer predicated in the sequence 
observed for the VP3 gene. Amplification of the VP2 gene was done, and cloning 
was accomplished with a VP2 gene which contained two AUG start codons in 
tandem. Stronger expression of several peptides was observed, however a level of 
expression observed for the VP3 fusion peptide could not be achieved with the 
modification introduced (gel not shown). Western blot analysis which used rabbit 
polyvalent antibody did not detect the fusion peptide in a definitive reaction, because 
of simultaneous development of background activity.
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Figure 13: Regulation of expression from recombinant plasmid TTQ-VP2.
Proteins from uninduced (lane 2), or induced cultures (lanes 3-7) were 
examined by SDS-PAGE using a 12% gel. (lane 1, molecular weight 
marker: lane 2, cells before ImM IPTG induction: lane 3, 1 hr after 
induction: lane 4, 2hr: lane 5, 3 hr: lane 6, 4 hr: lane 7, 5 hr: lane 
8, molecular weight marker).
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VP - 1
5’- CCG AAT TCT GTT GGA GAT GAT TCT GGA . . .
VP - 3
5’- CCG AAT TCT A T G  AGA AAT GAA TTT AGG . . .
VP - 2
5’- CCG AAT TCG GAC ATT GAG GAA GAG CAA . . .
VP - 2 ( + A U G )
5’- CCG AAT TCT A T G  GAC AAT GAG GAA GAG . . .
VP - 0
5’- CCG AAT TCT A T G  A AC A T G  TCT AGA CAA . . .
Figure 14: Design for the positive strand primer for the VP-2 (+AUG) based on 
the presence of tandem AUG’s in the 5’ termini of the VP-0 and VP-3 
capsid genes.
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Failure to identify the fusion product by Western Blot hybridization suggested 
three possible reasons. First, the failure of antibody recognition of the fusion 
peptide caused by its denatured state where conformational epitopes were destroyed 
and therefore not recognized by HAV-specific antibodies. Second, the VP2 peptide 
may not constitute a predominating epitope in the viral capsid and as a result may 
not induce antibody production. Third, the VP2 fusion peptide is not being 
expressed in the recombinant clone assayed since the protein background observed 
did not reveal a predominating or overexpressed peptide as previously observed for 
the VP3 recombinant.
A second approach used to clone of viral capsid genes was the pAX 
expression vector system. Figure 15 illustrates the gene organization for the 
pAX4b+ plasmid. This plasmid offered the advantage of providing a fusion peptide 
which contained the entire /S-galactosidase gene as the leader protein instead of the 
alpha-fragment present in pTTQ18. This provided a leader peptide useful for 
affinity purification of the fusion peptide, since the entire /3-galactosidase molecule 
was represented in the fusion peptide. The plasmid also provided a recognition site 
for endoproteinase Xa located in a hinge region between the leader peptide and the 
cloned protein, which permits the potential for cleavage and further isolation of the 
cloned viral peptide free of the /3-galactosidase leader peptide. Oligonucleotide 
primers were redesigned for amplification of the negative strands since the new 
vector lacked the Hindlll and BamRl sites used previously in the pTTQ18 
expression vector. Figure 16 displays the oligonucleotide primers designed for this
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cloning approach. The cloning steps are outlined in Figures 17a, 17b, and 17c. 
Successful cloning was confirmed by restriction endonuclease analysis of the 
recombinant plasmids and PCR amplification of the viral gene from the recombinant 
plasmid. The VP1 capsid gene was cloned first and expressed by addition of 1.3 
mM IPTG. Figure 18 illustrates the proteins from the recombinant clone resolved in 
a 7.5% discontinuous SDS-PAGE and stained with coomassie blue. The fusion 
peptide appeared at a higher molecular weight since the entire j8-galactosidase 
molecule (MW 116,250 Da) was added to the 33,000 Da viral peptide. Western 
blot hybridization with rabbit polyvalent serum and with the P2-G9 monoclonal 
antibody recognized the expressed peptide, depicted in Figures 19a and 19b. Minor 
non-specific recognition of the /3-galactosidase peptide, included in the marker lane, 
was observed with the monoclonal antibody following tenfold dilutions of the P2-G9 
monoclonal and after diluting the alkaline-phosphatase conjugated antibody to 
1:10,000. Rabbit polyvalent activity against endogenous anti-/?-galactosidase had 
been observed previously.
The next step examined was to produce large scale expression of the fusion 
peptides. The fusion peptides VPl(pAX4b-VPl) and VP3 (pTTQ18-VP3) were 
overexpressed in one liter cultures. Two approaches were considered for the 
purification of the /3-galactosidase fusion peptides. In the first protocol, a 
commercial anti-/3-galactosidase affinity column was used to selectively immobilize 
the peptides of interest from an ammonium sulfate-fractionated cell sonicate. Low 







Figure 15: Prokaryotic expression plasmid AX4b+. The general features 
illustrated in the figure include a collagen fragment (CS), 
endoproteinase Xa cleavage site (XJ, a multi cloning site (MCS), a 
Lambda terminator (t„), an fl origin of replication for isolation of 
single stranded DNA (fl ori), an ampicillin resistance marker (bla), the 
lacZ gene promoter (Plac), and the lacZ gene (lacZ).
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A x - l-N S
5’ CCC TGC AGG CTC AAA TCT TTT ATC TTC
I‘st I
A x -2 -N S
5’ CCA GAT CTT GTG TAG AAA GAG GAG T
Bgl II
A x -3 -N S
5’ CCC TGC AGT TTG TGT AGT AAC ATC CAT
Pst I
Figure 16: Negative strand oligonucleotide primers designed for cloning into the 3’ 
end of the multi-cloning site of the expression vector pAx4b+. (NS) 
Negative strand primer, (1) viral peptide gene 1, (2) viral peptide gene 
2, (3) viral peptide gene 3.
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a t c g a g g g t a g g g t c g g a c c a t g G A A T T  C g g t a c c a g a t c t a g a g t c g a C T G C A G ccc  
t a g c t c c c a t  c c c a g c c t g g t a c C T T  A A G c c a t g g t c t a g a t c t c a g c tG  A C G T  C g gg
Eco Rl Pst I
lacZ
Figure 17a: Outline of the approach followed for cloning of the HAV capsid
peptide gene (VP1) after PCR amplification. The blunt-ended PCR 
product contained different restriction endonuclease termini compatible 
with the plasmid vector. Selection of different restriction endonuclease 
sequences generating cohesive termini allowed for the directional 
cloning of the PCR fragment.
a t c g a g g g t a g g g t c g g a c c a t g G  G c c c
ACGTCggg
P st I  ------ -
TAGCTCCCAT C C C A G C C T G G T A C C T T  A A  
\  Eco Rl
pAX4 b +
6 2 0 2 bp
Figure 17b: Restriction endonuclease digestion of the blunt-ended PCR product and 
the plasmid vector generated the directional-cohesive termini for the 
ligation by the T4 ligase enzyme.
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Figure 17c: Illustration of the resulting cloned PCR fragment after ligation to the 
expression plasmid vector. Positive and negative strand 
oligonucleotide primers were designed to follow the reading frame of 
the multi-cloning site in the plasmid. The resulting fusion peptide 
contained the entire Beta-galactosidase molecule encoded by the lacZ 
gene resulting in a fusion peptide with an approximate molecular 
weight of 149,250 Daltons (B-gal (116,250 Da +  VP1 (33,0000 
Da).
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Figure 18: Regulation of expression from recombinant plasmid AX4b-VPl.
Proteins from uninduced (lane 7), or induced bacterial cells (lanes 3-7) 
were examined by SDS-PAGE using a 7.5% gel. (lane 1, molecular 
weight marker: lane 2, 5 hrs after 1.3 mM IPTG induction: lane 3, 4 
hr: lane 4, 3 hr: lane 5, 2 hr: lane 6, 1 hr: lane 7, cells before 1.3 
mM IPTG induction: lane 8, molecular weight marker).
Figure 19a: Western Blot analysis of expressed fusion peptides from recombinant 
plasmid AX4b-VPl against a rabbit polyvalent serum generated against 
the intact HAV. (Left panel) 7.5% SDS-PAGE from uninduced (lane 
7), or induced bacterial cells (lanes 2-6). (lane 1, molecular weight 
marker: lane 2, 5 hrs after 1.3 mM IPTG induction: lane 3, 4 hr: 
lane 4, 3 hr: lane 5, 2 hr: lane 6, 1 hr: lane 7, cells before 1.3 mM 
IPTG induction: lane 8, molecular weight marker). (Right panel) 
Western blot of SDS-PAGE. lane 7, uninduced cells: lanes 2-6, 
induced bacterial cells as in left panel: lane 8, Amersham Rainbow 
molecular weight marker.
Figure 19b: Western Blot analysis of expressed fusion peptides from recombinant 
plasmid AX4b-VPl against the neutralizing monoclonal antibody P2- 
G9. (Left panel) 7.5% SDS-PAGE from uninduced (lane 7), or 
induced bacterial cells (lanes 2-6). (lane 1, molecular weight marker: 
lane 2, 5 hrs after 1.3 mM IPTG induction: lane 3, 4 hr: lane 4, 3 
hr: lane 5, 2 hr: lane 6, 1 hr: lane 7, cells before 1.3 mM IPTG 
induction: lane 8, molecular weight marker). (Right panel) Western 
blot of SDS-PAGE. lane 7, uninduced cells: lanes 2-6, induced 
bacterial cells as in left panel: lane 8, Amersham Rainbow molecular 
weight marker.
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This low recovery suggested the possibility for a lack of epitope recognition 
in the alpha fragment of the /3-galactosidase molecule present in the fusion peptide. 
The VP-1 fusion peptide obtained from the pAX4b plasmid, and containing the 
entire /3-galactosidase molecule, was efficiently isolated and the purified fusion 
product was detected by electrophoresis as represented in Figure 20. The difference 
observed between the recovery of the viral peptide containing the alpha fragment or 
the entire /3-galactosidase could be explained by the fact that the antibody used to 
construct the affinity column is of monoclonal origin. Epitope recognition by 
monoclonal antibody occurs only when the fusion peptide contains the entire /3- 
galactosidase as opposed to the alpha fragment where the target epitope may not be 
represented.
A second approach used to circumvent the possible problems discussed 
above, was to utilize an affinity column constructed with rabbit polyvalent antibodies 
generated against intact HAV. Rabbit polyvalent serum was absorbed through the 
CNBr-Sepharose 4B matrix previously linked with the E. cob protein lysate to 
remove non-specific antibodies and enrich for anti-HAV antibodies. Following three 
consecutive fractionations in ammonium sulfate the globulin fraction was quantitated 
and linked to the Protein A Sepharose matrix. The matrix was packed into a column 
for affinity purification of the fusion peptides. Recovery levels were lower when 
compared to those obtained when the fusion peptides were isolated from the anti-/3 
galactosidase affinity column.
, :'N, ' v' •>■• J:-~
Figure 20: 7.5% SDS-PAGE of affinity purified VP1 fusion peptide from anti-/3
galactosidase matrix, lanes 1 and 4, molecular weight markers: lane 2, 
cell lysate after 1.3 mM IPTG induction (5 hr): lane 3, affinity purified 
VP1 fusion peptide.
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The isolated fusion peptides were concentrated and assayed by enzyme linked 
immunoassay against the rabbit polyvalent generated against the intact HA virus.
This assay constituted the test to demonstrate the feasibility of substituting 
recombinant peptides for intact HAV. Initial assays showed an improvement in the 
absorbance readings when the peptides were fixed by addition of 100 n 1 of a 0.5% 
Glutaraldehyde in 0.067M PBS for 30 min before the blocking step. For the fusion 
peptide VP-1, both rabbit polyvalent and the P2-G9 monoclonal recognized the 
peptide. The VP-3 fusion peptide also reacted with the polyvalent serum but not 
with the P2-G9 monoclonal which supported the established contention that 
neutralization activity (shown by the P2-G9 clone) was associated with the 
immunodominant VP-1 capsid peptide, and not the VP-2 and/or the VP-3 capsid 
peptides. ELISA findings in which the /3-galactosidase peptide was used as the 
antigen in the wells showed an increased antibody response in immune serum when 
compared to the pre-immune serum from the same experimental animal. Since the 
possibility that antibody recognition of the /3-galactosidase peptide accounted in part 
for the ELISA titers observed, cleavage of the fusion peptides was assessed.
Cleavage of the fusion peptides was attempted with the collagenase enzyme 
from Clostridium hystoliticum and with endoproteinase Xa from bovine plasma. 
Following treatment with collagenase of the upper band in the doublet disappeared 
as observed when the fusion product was electrophoresed (lanes 3 and 6, Figure 21). 
However, no band was observed at 33 KDa, which was the expected molecular 
weight for the VP1 peptide. Instead a protein band was observed above the 69 KDa
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molecular weight mark. The band did not react with the neutralizing monoclonal 
P2-G9 by western blot shown in Figure 22.
Next, the cleavage of the fusion peptide with the bovine endoproteinase X* 
was attempted. Effective cleavage was obtained when urea was incorporated into 
the reaction buffer. An accelerated rate of peptide digestion was detected when 
37°C incubation was used compared to 4°C. However prolonged incubation at low 
temperature (4°C) produced similar results. Figure 23 illustrates the enzyme digest 
results at different incubation temperatures. It can be seen that endoproteinase 
continues to digest both peptides, since several intermediate bands can be seen below 
the anticipated molecular weights of both the /3-galactosidase and the VP1 peptides, 
and no significant increase is observed for the digested viral peptide over the rest of 
the cleaved products. If a clean cleavage was produced the expected predominating 
protein bands are be the jS-galactosidase and the viral peptide. The stained gels and 
immunoblots showed a ladder of the digested products instead (Figures 24 and 25). 
Western blot analysis with the neutralizing monoclonal and the rabbit polyvalent also 
reacted with several bands. However the monoclonal reacted slightly more specific 
with protein bands appearing around the molecular weight expected for the VP1 
peptide (33 KDa). This results are illustrated in Figures 24 and 25 for the 
neutralizing monoclonal and for the rabbit polyvalent respectively.
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Figure 21: 7.5% SDS-PAGE of HAV-VP1 fusion peptide digested with the 
collagenase enzyme, lanes 1, 7, and 8, molecular weight markers: 
lanes 2 and 5, undigested HAV-VP1 affinity purified fusion peptide 
from two different preparations: lanes 3 and 6, collagenase digested 
fusion peptide: lane 4, cell lysate from recombinant strain carrying the 
plasmid pAX4b-VPl.
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Figure 22: Western Blot analysis of HAV-VP1 fusion peptide digested with 
collagenase enzyme. (Left panel), 12% SDS-PAGE of HAV-VP1 
fusion peptide digested with the collagenase enzyme, lanes 1, 7, and 8, 
molecular weight markers: lanes 2 and 5, undigested HAV-VP1 affinity 
purified fusion peptide from two different preparations: lanes 3 and 6, 
collagenase digested fusion peptide: lane 4, cell lysate from 
recombinant strain carrying the plasmid pAX4b-VPl. (Right panel) 
Western blot of SDS-PAGE.
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Figure 23: 12% SDS-PAGE of HAV-VP1 fusion peptide digested with the
endoproteinase Xa at different incubation temperatures, lanes 1, 6, and 
7, molecular weight markers: lane 2, undigested HAV-VP1 affinity 
purified fusion peptide: lane 3, 25°C: lane 4, 37°C: lane 5, 4°C.
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Figure 24: Western Blot analysis of the HAV-VP1 fusion peptide digested with the 
endoproteinase Xa at different incubation temperatures and reacted 
against the neutralizing monoclonal P2-G9. (Left panel) 12% SDS- 
PAGE of the HAV digested fusion peptide, lanes 1, 6, and 7, 
molecular weight markers: lane 2, undigested HAV-VP1 affinity 
purified fusion peptide: lane 3, 25°C: lane 4, 37°C: lane 5, 4°C. 
(Right panel) Western blot of SDS-PAGE.
Figure 25: Western Blot analysis of the HAV-VP1 fusion peptide digested with the 
endoproteinase Xa at different incubation temperatures and reacted 
against the rabbit polyvalent raised against the intact HA virion. (Left 
panel) 12% SDS-PAGE of the HAV-VP1 fusion peptide. lanes 1, 6, 
and 7, molecular weight markers: lane 2, undigested affinity purified 
fusion peptide: lane 3, 25°C: lane 4, 37°C: lane 5, 4°C. (Right 
panel) Western blot of SDS-PAGE.
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DISCUSSION
In vitro nucleic acid amplification by PCR has had an enormous impact in 
the advance of molecular biology applications facilitating the detection, selective 
amplification and further manipulations of DNA and RNA sequences of interest. 
Cloning of PCR products for applications in in vitro transcription and translation has 
proven to be a powerful tool when structure-function relationships of proteins are 
considered. It also provides a vehicle for the precise assessment of recombinant 
protein expression from selectively amplified and/or modified sequences. These 
advantages were considered for the study of recombinant peptides of the Hepatitis A 
virus. The technique provided the feasibility of precisely amplifying the viral gene 
of interest without any flanking sequences that may influence the three dimensional 
conformation and final folding of the in vitro synthesized peptide by including 
additional amino acids not present in the native peptide. This situation was 
confronted by Ostermayr et al. (64) where several cDNA clones were constructed 
based on the restriction endonuclease sites located throughout the entire cDNA. The 
disadvantage of this approach resides in the consideration of the final recombinant 
peptide obtained. If the antigenic properties of the viral capsid peptide are assessed, 
it is important to keep in consideration the three dimensional configuration of the 
native peptide in relevance to the availability of linear and/or conformational 
epitopes. The authors made use of several clones that upon expression generated 
recombinant peptides that either lacked or contained sequences not found in the
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original viral capsid peptide. In their study the clones found to generate 
recombinant peptides mimicking the natural antigenic sites corresponded to the 
capsid gene VP1 in the region comprising the first 60 amino acids of the NH2- 
terminal. No antigenic activity was found for the viral peptides VP2 or VP3 which 
is a much debated topic since some authors support VP1 as the sole neutralization 
epitope (22, 23, 40, 64), whereas the participation of VP2 and VP3 in the overall 
conformational neutralization epitope is supported by other researchers (3, 31, 39).
Cloning and expression of PCR amplified capsid genes also provided a means 
to circumvent the problems associated with isolating the viral peptides by disruption 
of the capsids. The later approach involves difficulties associated to the low 
amounts of purified viral capsid proteins obtained from either purified liver extracts 
or cell culture (40).
A cloned PCR product representing the entire extent of the viral gene 
expressed in a prokaryotic vector constituted a superior approach for the assessment 
of the individual antigenic properties. The antigenicity of the recombinant peptide 
can then be contrasted to the entire virion capsid where a conformational 
contribution from the three major viral capsid peptides is postulated (39, 76). After 
a survey of the existing data, where no clear division exists of whether one or more 
of the capsid peptides participates as the major neutralization epitope, the precise 
amplification, cloning, and expression of the three major capsid peptides deserved a 
detailed assessment. The potential applications of the research extended from 
substitution of tissue culture grown virus, currently used in immunodiagnostics, for
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recombinant viral capsid peptides, to the assessment of the generation of antibodies 
of polyclonal and/or monoclonal origin using the specific recombinant peptides.
The initial approach where blunt-end cloning was attempted was unsuccessful 
after several corrective measures were applied. One documented difficulty with 
blunt-end cloning of PCR products is the 3’ terminal nucleotide addition by a 
terminal transferase activity associated with Taq DNA polymerase (11, 19). The 
manipulations involved in correcting the ends of the amplified genes before cloning 
made this cloning approach too cumbersome to pursue.
Incorporation of restriction endonuclease sites as the flanking sequences to 
the oligonucleotide primers offered the advantage of orienting the cloning of the 
amplified PCR products in a forced-cloning approach. Recombinant clones were 
obtained by the approach with variable efficiencies of recovery observed. After 
assaying several variables such as ligation temperatures, ligation ratios, DNA 
concentrations, competent cell conditions, transformation and electrophoration, some 
improvements were observed as reflected by higher number of recombinants 
obtained. However, a common observation throughout the cloning experiments was 
a lower recovery of recombinants when the Eco Rl Wind III restriction endonuclease 
sequences was used for the positive and negative strand primers respectively. This 
was the case for the VP1, VP2, and VPO capsid genes. For the VP3-PCR amplified 
product an Eco Rl /Bam HI orientation was used since the capsid gene had an 
interna] Hind III site. This finding lead to the consideration of a Bam HI restriction 
site for the negative strand primer. The failure of some restriction endonucleases to
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cleave at sequences located near extreme ends of DNA fragments has been 
documented previously (46). However, in this particular study, the choice of 
restriction endonuclease sequences did not constitute a problem for the generation of 
terminal cohesive ends since successful ligation of each individual recombinant gene 
was demonstrated. This results supported the efficient digestion of the flanking 
sequences and the generation of the cohesive ends necessary for cloning.
When prokaryotic expression of the cloned capsid genes was assessed 
difficulties were observed again for the VP1, VP2, and VPO viral genes. Under the 
expression of the pTTQ18 tac promoter, only the recombinant VP3 fusion peptide 
showed efficient expression as demonstrated by SDS-PAGE and Western blot 
analysis. An explanation to the inefficient expression of the recombinant peptides 
can be considered from different angles such as the generation of a recombinant 
peptide toxic to the bacterial host, the possibility of degradation or protease digestion 
of the recombinant peptide, or the interrupted expression at the transcriptional 
and/or translational levels. The possibility of synthesizing a recombinant peptide 
toxic to the host seem unlikely since no variations in the cell numbers were observed 
before or after inducing expression of the recombinant clones. The possibility of 
protease degradation was ruled out by analysis of protein lysates at shorter time 
intervals after induction with the IPTG. No appearance of a recombinant product 
disappearing with time progression could be observed. Immunoblots also failed to 
detect any recombinant products even at a degraded stage. Maxicell analysis 
considered to study plasmid expression did not shed any light in the elucidation of
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the lack of expression for the cloned genes. Again, the VP3 recombinant plasmid 
showed signs of expression that was absent in the other recombinants but under a 
very high background that proved difficult to eliminate after increased doses of 
ultraviolet exposure.
The restriction endonuclease-directed cloning approach in the pAX4b vector 
was initially considered for the VP1 capsid peptide. After efficient cloning into Eco 
Rl/Pst I sites followed by IPTG induction a product was demonstrated by SDS- 
PAGE and Western blot analysis with a rabbit polyvalent and the monoclonal P2- 
G9. However, the recombinant product expressed appeared as a doublet in 
coomassie blue stained gels and immunoblots, suggestive of two stop points during 
the transcription and\or translation events. In addition to this observation the 
recombinant product resolved by SDS-PAGE showed a lower size than expected 
suggestive of a difficulty at the expression level instead of the possibilities of 
protease digestion or toxicity brought by the expression of the recombinant product.
The results demonstrated that at least two viral capsid peptides, VP1 and VP3 
possessed and retained antigenic properties as demonstrated by Western blot analysis 
using a polyvalent serum generated against the intact Hepatitis A virus. The VP1 
recombinant peptide was also recognized by the hybridoma P2-G9 which had been 
shown to possess neutralizing activity. The results from the mentioned assays 
support the predominance of at least the VP1 and VP3 peptides as epitopes in the 
intact HA virion and suggest the presence of preserved epitopes even under 
denaturing conditions such as the ones assayed in this study.
135
Affinity chromatography revealed more efficient isolation for the fusion 
peptides expressed with the entire /3-galactosidase in the pAX4b system. The 
purified peptide was shown in Figure 20. The recovery observed for fusion peptides 
containing only the alpha fragment of the /3-galactosidase was approximately tenfold 
below. This was apparently due to the poor recognition or absence of /3- 
galactosidase epitopes relevant for the affinity purification of the fusion peptides 
containing only the alpha (a) fragment.
Assessment of the peptides in an enzyme immunoassay confirmed the 
necessity of cleaving the /3-galactosidase portion of the molecule to definitely 
exclude any false reactions caused by recognition of the /3-galactosidase by 
antibodies that may be present in normal serum.
Cleavage of the peptides was more effective with the endoproteinase Xa than 
with the collagenase. The digestion of the peptide proceeded beyond the recognition 
of the endoproteinase target site since several protein bands could be observed in the 
stained gels and the Western blots developed with the monoclonal and polyclonal 
antibodies. This observation is suggestive of the existence of target sequences along 
the /3-galactosidase and the VP1 peptide. Thirteen arginine residues can be found in 
the aminoacid sequence of the VP1 peptide. Only two of these arginine residues are 
found as part of potential sequences for endoproteinase recognition (14). Control 
reactions where the peptides were exposed to the digestion conditions in the absence 
of the endoproteinase excluded the possibility of non specific degradation. The 
requirement for a denaturant agent such as urea suggests the possibility of the viral
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portion of the peptide being occluded in the entire recombinant peptide. Effective 
isolation of the cleaved peptides could require use of techniques such as exclusion 
chromatography or HPLC to specifically isolate the 33 KDa recombinant viral 
capsid peptide on the basis of its molecular weight. On the other hand, if the 
production of specific antisera and/or monoclonal antibodies is pursued, the peptides 
could be processed in various different ways without the requirement for cleavage as 
described by Oettinger et.al. (60).
CONCLUSION
The antigen capture assay developed for the detection of the Hepatitis A virus 
showed a lower than expected sensitivity level. The assessment of the serological 
reagents developed and utilized in the assay pointed to the posibility of the interference 
due to the formaldehyde used to preserve the viral particles. Due to the impediment 
in assessing the assay conditions with the non-inactivated virus, the question pertaining 
to the formaldehyde interference remains pending. Due to the limited access to the 
native Hepatitis A virus, the initiative to generate the capsid peptides as recombinant 
molecules was pursued. The recombinant peptides showed antigenicity by immunoblot 
and enzyme immunoassay demonstrating the potential for the generation of recombinant 
viral peptides as an antigen source and for applications in immunoassay development 
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